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Abstract 
 
Natural Killer (NK) cells are lymphocytes of the innate immune system killing 
skills against infected or transformed cells, without prior signaling. NK cells represent 
5
-
20% of peripheral blood lymphocytes and based on their functions NK cells are 
subdivided into two subsets CD56
bright
CD16
-
 (cytokine production) and CD56
dim
CD16+ 
(cytotoxicity). Chronic myeloid leukemia (CML) is a genetic myeloproliferative disease 
and previous studies indicate that NK cells are deficient in CML patients, although the 
mechanisms behind the dysfunction are not completely understood. The main goal of 
this work was to contribute to the cellular understanding of the insufficient control of 
NK cells over malignant CML cells. For this propose, we analyzed 62 blood samples 
from CML patients and 4 from healthy donors. All samples are labelled with extra or 
intracellular antibodies and through flow cytometry, we analyzed the expression of 
some surface markers, receptors and cytokine production NK cells from CML patients. 
In this study we demonstrate that NK cells from CML patients are reduced in number 
and the expression of cell surface markers and receptors, and cytokine production are 
altered. Besides that we reported that different biologic and TKI therapies affect in 
different ways the NK cells as well as imatinib dosage. We conclude that CML patients 
actually have dysfunctional NK cells, which reveal a dysfunction in the immune 
response against the disease. Thus, understand how these cells are affected can bring 
new developments in the treatment of these patients, particularly through modulation of 
NK cells, strategies to boost its activity. 
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Resumo  
 
As células Natural Killer (NK) são linfócitos granulares com capacidade de 
matar células infectadas ou transformadas sem sinalização prévia, para além de 
produzirem citocinas que permitem modular a resposta imune inata e adaptativa. 
Representam cerca de 5-20% dos linfócitos no sangue periférico e, com base na sua 
função, são divididas em duas subpopulações CD56
bright
CD16
-
 (produção de citocinas) e 
CD56
dim
CD16+ (citotoxicidade). A Leucemia Mielóide Crónica (CML) é uma doença 
genética mieloproliferativa e estudos anteriores indicam que células NK de doentes com 
CML são disfuncionais, mas os mecanismos que estão por base destas disfunções não 
estão ainda bem definidos. Desta forma, o principal objectivo deste trabalho é contribuir 
para o entendimento do controlo insuficiente das células NK sobre as células 
leucémicas. 62 Amostras de sangue de doentes com CML e de 4 dadores saudáveis 
foram analisadas. Todas as amostras foram marcadas com anticorpos e, por citometria 
de fluxo, analisamos a expressão de alguns marcadores, receptores e a produção de 
citocinas nas células NK. Neste estudo demonstramos que a frequência das células NK 
de doentes com CML está diminuída e a expressão de marcadores de superfície, 
receptores e a produção de citocinas está alterada. Para além disso, reportamos também 
que diferentes tipos de terapia ou a dosagem do fármaco têm diferentes efeitos nestas 
células. Concluímos então que os doentes com CML têm disfuncionalidades ao nível 
das células NK, o que indica uma disfuncionalidade na resposta imune do organismo 
contra a doença. Assim, entender como estas células estão a ser afectadas pode trazer 
novos desenvolvimentos no tratamento destes doentes, nomeadamente por modulação 
das células NK, estratégias que permitam potenciar a sua actividade. 
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Immune System 
 
 The immune system is complex machinery, involving an intricate molecular and 
cellular organization with specific and specialized roles against pathogens, substances 
that can cause illness or death (2). 
 Classically, there are two different types of immune frontiers, external and 
internal defenses (2). Nowadays, the organization of immune system consists into three 
phases based on the timing of response (3). Mechanical defenses such as the skin and 
mucous membranes that line digestive and respiratory tracks act instantly to prevent 
body tissues, innate immune defenses and adaptive/acquired immune defenses, both 
comprise a variety of specialized cellular and humoral components (3). Innate and 
adaptive systems combined represent the internal defenses seen as cellular antigen
-
specific processes (2). 
 Hematopoietic stem cells are produced lifelong and same cells produce all the 
classes of leukocytes(3). Based on function these cells are divided into three major 
groups, phagocytes, lymphocytes and cells containing cytoplasmatic granules (3). 
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Figure 1: Hematopoietic stem cells differentiation. Cells of the immune response as well as 
of the blood arise by differentiation from hematopoietic stem cells. Platelets are cell fragments 
involved in the clotting of blood (3). 
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Innate & Adaptive Defenses 
 
 Fundamentally, the immune system is been allocated into two branches, innate 
and adaptive immunity. Both immune responses results from an unbalanced integration 
of positive and negative signals that have impact on both innate and adaptive cells (4). 
When positive signals prevail, cell activation and pro
-
inflammatory responses succeed 
with resultant elimination of microorganisms and viruses, when inhibitory signals 
dominate or in absence of productive stimulation cell activation is blocked (4). The duel 
between stimulation/inhibition occurs through cell
-
cell contact, by cytokines and 
signaling pathways downstream (4). 
 Innate immune system is fast and less specific and can be divided in cellular and 
humoral immunity. Cellular components are NK cells, APCs and other phagocytes, 
representing the organism first internal defense (2). 
 APCs, dendritic cells and macrophages, have the ability to recognize internal 
dangers through antigen recognition, and thus exert its  effector action or present them 
to other immune cells from both innate and adaptive system, acting like a dynamic 
bridge between them (2). Humoral compounds include complement proteins and 
cytokines (2). 
 The adaptive system is highly specific and can be divided in humoral 
compounds related to antibodies release by the B lymphocytes, and cellular components 
associated with T lymphocytes and memory response, allowing an improvement on 
repeated exposure to a given infection (2). Adaptive immunity in mammals is 
characterized by two types of lymphocytes, T and B lymphocytes are the main self
-
defensive weapons of the adaptive immune responses, triggered by antigen exposure 
(5).T and B cells clonally expressing a large repertoire of antigen receptors produces by 
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site
-
specific somatic recombination, TCRs and BCRs (6).  Functionally, naïve B and T 
cells target antigens in lymphoid organs and promote cell division and maturation 
before exerting their effector functions (6). The innate immunity distinctive features are 
commonly refer to fast “time of reaction” and broadly variety of myeloid and lymphoid 
cells that only need a few minutes of exposure to exert their effector functions, put 
forward a protective inflammatory response and if necessary lead off an adaptive 
response (5,6). 
 
Figure 2: Integrated human immune system. The human microbial defense system can be 
simplistically viewed as consisting of 3 levels: anatomical and physiological barriers; innate 
immunity; adaptive immunity (5). 
 
 Innate and adaptive responses work by themselves and together with the same 
purpose, organism protection from danger (7). The combination of both enables the 
immune system to recognize and eliminate invading pathogens with maximal efficacy 
and minimal damage to self, also providing protection from re
-
infection (7). 
  
Characterization of Natural Killer Cells in Chronic Myeloid Leukemia Patients 
7 
Innate Immunity 
 
 From a phylogenetic standpoint, the innate immunity evolved long before the 
adaptive immune system, and homologous components can be found in invertebrates 
and plants (8). Although it might appear primitive, the innate immune system has 
recently been recognized to be more complex and sophisticated than previously thought 
and it is now increasingly clear that several aspects of the adaptive immune response are 
controlled by the innate response (9). 
 The focus on innate immunity dates to the 1908 Nobel Prize
-
winning efforts of 
Ilya Mechnikov, but until the last decade its study has been covered by severe 
discoveries in adaptive immunity field (5). Currently, the recent molecular definition of 
how the innate immune system senses infection to enhance protective immune 
responses has precipitated a renaissance in this campus. The title “nonspecific 
immunity” is no more connected with innate immune system, now being regarded as a 
powerful partner of adaptive system (5). 
 Innate immune responses are not specific to a particular pathogen in the way that 
the adaptive immune responses are (2). The innate immune cells distinguish infectious 
agents and/or abnormal “self” from normal “self” molecules, using germline encoded 
receptors. The cellular compartment is represented by granulocytes, mast cells, 
monocytes, macrophages, DC and NK cells (9). Although each cell type has specific 
functions, they cooperate to orchestrate effective immune responses. Besides that they 
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provide direct elimination of infectious agents and induce the adaptive immunity 
developing, manipulating the quality and strength of the immune response (5,9). 
 
Figure 3: The innate and adaptive immune cells and soluble components. Innate immunity 
consists of soluble factors, such as complement proteins, and diverse cellular components 
including granulocytes (basophils, eosinophils and neutrophils), mast cells, macrophages, 
dendritic cells and natural killer cells. Adaptive immunity consists of antibodies, B cells, and 
CD4+ and CD8+ T lymphocytes. Natural killer T cells and γδ T cells are cytotoxic lymphocytes 
that straddle the interface of innate and adaptive immunity (10).  
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Innate Immune Recognition 
 
 The innate immune system uses at least three strategies in order to recognize 
invading microorganisms (5). Cells from innate defenses recognize “microbial nonself” 
conserved molecular structures that are expressed by a variety of microorganisms. 
Indeed, Charles Janeway invented the terms PRRs to collectively describe such 
receptors and PAMP to nominate the microbial structures recognized by the PRRs (5). 
TLRs are PRRs that are expressed on both lymphoid and non
-
lymphoid tissues, 
especially APC such as DC and macrophages (11). TLR
-
PAMP targeting initiates 
intracellular signal transduction cascades that lead NF
-
kB activation and the 
upregulation of adhesion and costimulatory molecules, and cytokines that are essential 
to aware the immune system for the presence of an intruder (5) (figure 4). The innate 
system has the capacity to detect immunologic danger in form of DAMPs related 
molecules that are commonly released and upregulated during the cell lysis and tissue 
damage, molecules often found in the tumor microenvironments (5).  
 
Figure 4: Inflammatory response via PAMPS/DAMP
-
TLR. Infection and cell injury result in 
the production of PAMPs and DAMPs that promote the inflammatory response via TLRs 
located on the cell membrane (11). 
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 Another strategy of recognition was described, based on the “missing self” 
hypothesis, innate immune receptors, namely Natural Killer cells (NK cells) receptors, 
detect molecules expressed by normal healthy cells but not expressed by infected cells 
or microbes. Recognition and tolerance of “self” induces an inhibitory signal, 
preventing the action of the immune system against host healthy cells (5). 
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Natural Killer Cells 
 
 NK cells were originally described in 1975 as large granular lymphocytes with 
capacity to kill in vitro tumor target cells without prior sensitization (12,13). At present, 
NK cells have gained recognition for their ability to secrete proinflammatory and 
antiviral cytokines, to recognize and eliminate tumors, viral and parasitic infections as 
well as normal allogeneic cells and to have regulatory functions in the context of the 
adaptive immune response (14,15). 
NK cells are usually considered to be constituents of innate immune defense, being 
actually one of its pillars, because they lack antigen
-
specific cell surface receptors (14). 
NK cells have been shown in humans and mice to participate in the early control against 
virus infection, especially herpesvirus infection (16), and in tumor immunosurveillance 
(15,17). 
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Immunobiology of NK Cells 
 
 Natural killer (NK) cells are innate immune lymphocytes capable of killing 
target cells and producing immunoregulatory cytokines.  
NK Cells Subsets, Distribution and Characterization 
 
 NK cells are large granular cells that have a common progenitor with B and T 
cells. All of them are originated in the bone marrow from CD34+ hematopoietic 
progenitor cells and are widespread throughout lymphoid and non
-
lymphoid tissues. 
They constitute 5
-
25% of PBMCs and up to 5% of the whole lymphocyte population in 
lymph nodes (14). Furthermore, NK cells can be found throughout most tissues 
including liver, spleen and lungs (18). Several studies have also described the existence 
of NK cells in the uterine mucosa, where they promote vascularization of implanting 
embryos during pregnancy (19).  
 NK cells are conventionally defined as CD56+CD3
-
, in peripheral blood NK 
cells comprise approximately 10% of all lymphocytes based on surface density of CD56 
(NCAM) and CD16 (FccRIII). Thus, NK cells are usually divided into two 
subpopulations CD56
bright
CD16
-
 and CD56
dim
CD16+ NK cells (20). CD56
bright
CD16
-
 
has a more immunoregulatory character and has a higher rate of cytokine production, 
whereas CD56
dim
CD16+ has more cytotoxic power and produce less cytokines (21). 
CD56
bright
 NK cells account for around 10% in peripheral blood and are the 
predominant subset found in secondary lymphoid tissues. CD56
dim
 NK cells represent 
the vast majority in peripheral blood accounting for up to 90% of all NK cells, but are 
rare in lymph nodes. They express high levels of FcγRIII (CD16) and are cytotoxic. 
Both subsets also differ in the distribution of NK cells receptors and in their 
proliferative response (22). 
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Figure 5: Model of NK cell developmental checkpoints. Checkpoints in NK cell 
development, expression of developmental markers, cytokine receptors, natural cytotoxicity 
receptors, and functional competencies (23). 
 
NK Cells Effector Functions  
 
 In literature, two major functions are associated to NK cells, cytokines and 
chemokines production and cytotoxic activity. Thus, NK cells could be classified as 
immunoregulatory and cytotoxic cells (15). NK cells are also involved in shaping 
adaptive immune responses through their production of cytokines (12). Recently, mouse 
NK cells demonstrate immune memory, similar to T lymphocytes, after viral infection 
(12). These kinds of developments in the NK cells area have been particularly 
intriguing, given the interest in developing strategies to apply NK cells as therapeutic 
agents against a broad range of malignancies as augmenting the activity of NK cells 
during chronic infections (12). NK cells exert two major effector mechanisms: 1 – 
Recognition and killing of target cells through perforin and granzyme release, as well as 
expression of death receptor ligands. 2 – Activation and recruitment of other immune 
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cells by secretion of cytokines and chemokines (24)(figure 6). Transformed or infected 
cells upon direct contact and recognition by NK cells leads to the activation of NK cell 
mediated cytotoxicity, as well as via ADCC through engagement of FcγRIII receptor 
(CD16) (25).  
 
Figure 6: Multiple signals control NK cell responses. An array of NK cell activation receptors 
bind to ligands on other cells. Target cell killing requires signals for lytic granule polarization and 
degranulation. Combinations of coactivation receptors synergize to induce killing and a secretory 
response. Some of the secretory response is independent of transcription. Inhibitory receptors for MHC-I 
exert dominant inhibition of cytotoxicity and secretion, as seen in the NK cell–dendritic cell interaction. 
Dendritic cells also receive signals from ligands on NK cells. In the absence of inhibition through MHC-I, 
target cells that express ligands for activation receptors are killed. NK cells respond to various soluble 
activators, such as cytokines and chemokines, that deliver signals for functions such as migration and 
survival  (26). 
 Perforin/granzyme via represent the main cytotoxic pathway, perforin and 
granzymes are stored in granules inside NK cells and get released by exocytosis upon 
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target cell recognition. Perforin molecules form a pore in the target cell membrane 
which enables granzymes to enter into the cytoplasm and initiate the apoptotic process 
(27). Other mechanisms include induction of apoptosis via TRAIL or engagement of the 
Fas receptor on the target cell surface via Fas
-
L (28). 
 Have been described NK cells regulatory capacities, which are mediated by 
various cytokines, such as IFN-γ, TNF-α, IL-10, IL-13 and/or GM-CSF, released upon 
engagement of triggering NK cell receptors or signaling by other cytokines (29). 
 Finally, the intensity and the quality of the NK cell response are regulated and 
depend on the NK cell microenvironment (e.g. presence of cytokines), as well as on the 
interactions with other cells of the immune system that cooperate to promote NK cell 
“priming” (13). IFN-γ and some interleukins (e.g. IL-1, IL-12 and IL-18) are potent 
activators of NK cell effector functions, whereas other interleukins (e.g. IL-15 and IL-2) 
are important for NK cell maturation, proliferation, and survival, cytotoxicity and 
cytokine secretion. Instead, NK cell function can be negatively regulated by TGF-β), 
and regulatory T cells through a TGF-β-dependent mechanism (13). 
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Target Cell recognition 
 
 The mechanism that allows NK cells to discriminate target cells remained a 
mystery for a long time. In 1981, Klas Kärre made a key contribution postulating the 
“missing self-hypothesis”. This concept was based on the observation that NK cells kill 
target cells lacking self MHC class I molecules, whereas normal MHC class I surface 
expression levels protects healthy autologous cells from lysis (30). 
 NK cells acquire tolerance to “self” during their development and maturation 
through a process called “licensing or “education”. Tolerance to “self” requires 
recognition by NK cell inhibitory receptors of self MHC-1 molecules that are expressed 
in the steady
-
state condition (31). Yet, in order to activate NK cells, other signals 
triggered by the engagement of specific activating receptors are required (32). 
According to the current “dynamic equilibrium paradigm”, the balance between 
inhibitory and stimulatory signals received by a NK cell determines the outcome of the 
interaction with the target cell (32).  
 NK cells can recognize a variety of stressed cells in the absence or in the 
presence of antibodies, NK cells can directly trigger stressed cells and kill them – 
“Natural Killing” or can act by the antibody dependent cellular cytotoxicity – ADCC, 
leading to target cell death by apoptosis (28). NK cells preform three mechanisms of 
recognizing and became or not activating in line with ligands express by the target cells 
(33). These mechanisms are based essentially in the expression of MHC-1 molecules 
NK cells inhibitory receptors recognize MHC-I molecules and then block the activating 
signaling cascade which confer tolerance by the NK cells (33). So, if the NK cells 
recognize a target cell and don’t became active means that these cells are “self” 
material, if the target cell lacks the presence of MHC-I molecules activating signals will 
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prevail and NK cells act in order to destroy them, these constitutes the hypothesis of 
“missing-self” recognition (figure 7). Furthermore, NK cells can act against cells that 
express MHC-I molecules too, since the activating signals overcomes the inhibitory 
signals, induced
-
self recognition (33). 
 
Figure 7: Recognition of tumor cells by NK cells. a) Natural killer (NK) cells are tolerant to 
healthy host cells; b) NK cells become activated when tumor cells lose expression of MHC 
class I molecules; c) ‘Stress-induced self’ triggering, NK cells are selectively  activated by 
‘stressed’ cells, which upregulate activating ligands for NK cells and thereby overcome the 
inhibitory signaling delivered by MHC-I molecules (13). 
 
 Recently, NK cells and DC have been demonstrated some cross
-
talk with each other in 
many different ways, including the NK cell killing of immature DC and the promotion of DC 
maturation, through cytokines released by NK Cells. Besides that DC can also promote the 
activation of NK Cells, and all together have crucial effects on adaptive responses (28). 
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Inhibitory and Activating NK Cells Receptors 
 
 To perform its functions NK cells require the expression of a highly organized 
diversified repertoire of activating and inhibitory receptors, the balance between 
positive and negative signals, respectively, controls the tolerance of NK cells to the 
other cells, and allows the immunosurveillance of the organism (15). NK cells have a lot 
of receptors, of different families, but the most crucial difference between all of these 
receptors is the negative or positive sort of signaling. The complex interactions, which 
regulate both the quality and magnitude of the ultimate response, depend on two short 
conserved motifs found in intracellular domain of various signaling proteins (15,34).  
 
Figure 8: Control of NK cell activation by SHP-1. In NK cells, engagement of NKG2D by its 
ligands on target cells triggers tyrosine phosphorylation of DAP10 by SFKs (at the tyrosine
-
isoleucine
-
asparagine
-
methionine motif). This phosphorylation triggers the recruitment and 
tyrosine phosphorylation of downstream effectors. When a KIR is engaged by its ligand, class I 
major histocompatibility complex molecules (MHCI), also present on target cells, SFKs 
phosphorylate the ITIM of the KIR, thus triggering the recruitment and activation of SHP-1. 
SHP
-
1 mediates the inhibition of NK cells by dephosphorylating the activating tyrosine residues 
of SFKs, as well as various intracellular tyrosine
-
phosphorylation substrates (34). 
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 ITAMs and ITIMS are the terms for immunoreceptor tyrosine
-
based activation 
(or inhibitory) motifs, provide the basis for two opposed signaling modules that 
compete for NK cell activation control within the immune system (35). 
 Upon ligand binding, activator receptors like TREM2, SIRP1, FcRI or FcγRIIIA 
associate with ITAM containing adaptor proteins such as DAP12. Subsequently, 
members of Src kinase family (SKF) phosphorylate tyrosine residues of ITAMs. 
Phosphotyrosine residues are docking sites for Syk protein kinases that upon activation 
mediate cellular activation via a number of downstream cascades. Upon ligand binding, 
inhibitory receptors recruit SHP-1 and SHP-2 which can in turn terminate intracellular 
signals emanating from ITAM receptors (34,35). Hence the balance between these two 
classes of receptors is the major target of NK cell modulation (35) (figure 8). 
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NK Cells – Fighting Cancer 
 
 The relationship between the immune response and tumors was addressed by the 
concept of cancer immunosurveillance that was presented in 1950s by Lewis Thomas 
Paul and then developed by Sir Macfarlane Burnet (36). This hypothesis supports the 
proposal of Ehrlich and other researchers that the immune system protects self
-
cells and 
destroys non
-
self cells. The hypothesis advocates that the human body develops tumor 
cells all the time, but these cells are routinely recognized and eliminated by the immune 
system. Therefore, tumor progression is a result of the immune system’s failure to clear 
tumor cells (24,37). 
Different mechanisms are known to be involved in the destruction of tumor cells 
by NK cells (10) (figure 9). Three types of mechanisms have been described until now, 
perforin/granzyme
-
mediated cytotoxicity, death receptor mediated apoptosis and 
Interferon
-γ effector functions (38). The perforin/granzyme-mediated cytotoxicity is the 
release of cytotoxic granules composed of perforin and granzymes is the fastest and also 
the most powerful way to lyse tumor cells (38). By creating a synapse with the target 
cell, NK cells will drop, at this junction, perforin and granzyme molecules inducing the 
lysis of the target cell (10,38). Death receptor mediated apoptosis refers to the death of 
the target cell, induced by apoptosis via TNF family ligands, Fas ligand and TRAIL, an 
alternative way to release granules (38). IFN-γ effector functions occurs after NK cells 
activation, these cells secrete various cytokines like IFN-γ, TNF-α, GM-CSF, IL-10, or 
IL-13 and their antitumor activities can be mediated by IFN-γ (38). Indeed, IFN-γ 
produced by NK cells contributes to eliminate tumor metastases, inhibition of 
proliferation of tumor cells, and has been also described to enhance NK cell cytotoxicity 
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by overexpressing adhesion molecules or by increasing the sensitivity of tumor cells to 
cytotoxicity mediated by granule release or death receptor engagement (10,38).  
 
 
 
Figure 9: A coordinated cellular and humoral reaction by NK cells mediates tumor 
destruction. Following stimulation, NK cells can lyse tumors through the perforin/granzyme 
pathway or apoptosis
-
inducing ligands such as TRAIL. NK cells secrete IFN-γ), which inhibits 
tumor
-
cell proliferation, enhances tumor
-
cell apoptosis, improves tumor antigen presentation 
and inhibits angiogenesis. NKT cells also execute cytotoxicity and cytokine production. 
Cytotoxic CD8+ T cells lyse tumors through death ligands, such as TRAIL, and the 
perforin/granzyme pathway. CD4+ T cells can differentiate into T helper 1 (TH1) cells that 
secrete IFN-γ and TNF-β or T helper 2 (TH2) cells that secrete IL-4, IL-5, IL-6, IL-10 and IL-
13. The latter cytokines enhance eosinophil function and increase antibody production by B 
cells. Antibodies to cancer cell
-
surface molecules can inhibit oncogenic signaling and/or 
stimulate tumor destruction through engaging Fc receptors on macrophages, granulocytes and 
NK cells (not shown). Antibodies can further promote tumor antigen presentation by DCs 
through immune
-
complex formation. Macrophages can lyse tumors through the production of 
nitric oxide and reactive oxygen species. Tumor blood vessels can also be attacked by 
lymphocytes and granulocytes (10). 
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Chronic Myeloid Leukemia 
 
 Sawyers’s in a review article defines CML as “a malignant clonal disorder of 
hematopoietic stem cells that results in increases in not only myeloid cells but also 
erythroid cells and platelets in peripheral blood and marked myeloid hyperplasia in the 
bone marrow” (39). Chronic myeloid leukemia (CML) is a clonal disorder in which 
cells of the myeloid lineage undergo inappropriate clonal expansion, caused by a BCR
-
ABL fusion gene resulting from a balanced translocation between the long arms of 
chromosomes 9 and 22, t(9;22)(q34;q11), also known as the Ph (40). The resulting 
fusion protein BCR
-
ABL is a cytoplasmic oncoprotein of 210 kDa with constitutively 
activated tyrosine kinase responsible for the clinical features of CML. The disease 
typically progresses through three distinct phases, chronic phase, accelerated phase, and 
blast crisis, during which the leukemic clone progressively loses its ability to 
differentiate (41).  
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Molecular Biology 
 
 The t(9;22)(q34;q11) translocation juxtaposes the 30 segment of the c
-
ABL 
oncogene (normally encoding the Abelson tyrosine kinase) from the long arm of 
chromosome 9 to the 50 part of the BCR gene on the long arm of chromosome 22, 
resulting in one shortened chromosome 22 (22q) (the Ph chromosome) and one 
elongated chromosome 9 (9q) (41) (figure 10). At diagnosis, the Ph is present in 
approximately 95% of CML cases (41). The molecular consequence of t(9;22)(q34;q11) 
translocation origins a gene that is expressed as a BCR
-
ABL mRNA transcript, 
translated into a 210
-
kDa protein known as p
210 
BCR
-
ABL (41,42). 
 
Figure 10: Philadelphia chromosome. Balanced translocation t(9,22)(q34: q11) 
translocation. This mutation is present in most cases of CML (>95%) (42).  
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 BCR
-
ABL oncoprotein acts as a constitutively active tyrosine kinase that can 
phosphorylate a large range of cytoplasmic substrates, giving advantage to proliferation, 
differentiation, adhesion, and survival (43). The effects of BCR
-
ABL oncogene leads to 
an uncontrolled signal transduction, effectively by increasing proliferation, motility and 
myogenic outcomes, and decreasing cell adhesion, differentiation and apoptosis (42,43). 
The leukemic clone in CML has a tendency to acquire additional oncogenic mutations 
over time, usually associated with progression to accelerated phases of disease or 
resistance to tyrosine kinase inhibitors (TKIs) (43,44). 
 
Figure 11: BCR
-
ABL signalling in chronic myeloid leukemia. With the aid of several 
mediator proteins, BCR
-
ABL associates with Ras and stimulates its activation. The adaptor 
protein, growth factor receptor
-
bound protein 2 (GRB2), interacts with BCR
-
ABL through the 
proximal SRC homology 2 (SH2)
-
binding site that develops when the tyrosine 177 (Y177) 
residue of BCR
-
ABL is autophosphorylated. GRB2, when bound to BCR
-
ABL, interacts with 
the son of sevenless (SOS) protein. The resulting BCR–ABL–GRB2–SOS protein complex 
activates Ras. The adaptor proteins CRKL (CRK
-
like) and SHC (SH2
-
containing protein) can 
also mediate the BCR
-
ABL activation of Ras. Ras and the mitogen activated protein kinase 
(MAPK) pathway are coupled by Raf (a serine/threonine kinase). Raf catalyses the 
phosphorylation of the mitogenactivated and extracellular
-
signal regulated kinase kinases 1 and 
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2 (MEK1 and MEK2); this results in their activation. Through the stimulation of the Ras–Raf 
pathway, BCR
-
ABL increases growth factor
-
independent cell growth. BCR
-
ABL also associates 
with and activates the phosphatidylinositol
-
3 kinase (PI3K) pathway, suppressing programmed 
cell death and increasing cell survival. BCR
-
ABL is associated with components of the focal 
adhesion (that is, actin, paxillin and focal adhesion kinase, or FAK); the activation of CRKL–
FAK–PYK2 leads to a decrease in cell adhesion. BCR-ABL also associates with the Janus 
kinase and signal transducer and activator of transcription (JAK–STAT) pathway. Finally, BCR-
ABL activates pathways that lead to atypical responses to chemotactic factors, which leads to an 
increase in cell migration. BCR
-
ABL also associates with survival proteins that interact with the 
mitochondrial
-
based BCL2 family. CAS, p130 CRK
-
associated substrate; GAB2, GRB2
-
associated binding protein 2; SHIP, SH2
-
containing inositol
-
5
-
phosphatase (44). 
 
 
 Once well established the molecular biology of CML cells, the researchers had 
the “open doors” to develop targeting drugs for BCR-ABL metabolic pathways (45). 
The BCR
-
ABL protein is unique to leukemic cells, being expressed in high levels and 
its tyrosine kinase activity is essential for its ability to induce CML. Thus, BCR
-
ABL 
protein is an ideal and attractive target for CML therapies (46).  
Clinical Features 
 
 With an annual incidence of approximately 1.5/10
5
 CML is a rare genetic 
disease that affect most males than females (ratio 1.7:1) and the incidence greatly 
increases in older population (average 45
-
50years), but doesn’t show significant ethnic 
or geographical predisposition. Symptoms comprise fever, weight loss, and abdominal 
fullness, but the majority of patients are asymptomatic at diagnosis (47). The clinical 
course of CML is three
-
phased with gradually severe over each phase, chronic and 
accelerated phase, and blast crisis. Most patients are diagnosed in the chronic/stable 
phase – expansion of the myeloid cell compartment, cellular differentiation and function 
is maintained – and after a variable length of time the disease progresses to blast crisis, 
which look like an acute myeloid (70%) or lymphoid (30)% leukemia (39). Before the 
drug therapy approval for CML the patients were treated with interferon
-α-based 
regimens, the median duration of the chronic phase was approximately five years (48). 
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Timeline Treatment 
 
 In 1960, investigators in Philadelphia identify a chromosomal abnormality 
linked to a specific form of leukemia called chronic myelogenous leukemia (CML). A 
decade later, further research by Janet Rowley leads to the discovery that this 
abnormality occurs when two chromosome fragments – chromosomes 9 and 22 – switch 
places in a phenomenon called balanced translocation (40).  
 Since 1970s, allogenic stem cell transplant (allo
-
SCT) has been used as the only 
therapy that effectively could eradicate leukemic clones. However, a higher risk of 
mortality has been associated with this therapy and in addition some constraints like 
age, disease status, time from diagnose and recipient
-
donor gender combinations must 
be taken in account (49). In the early 1980’s, Interferon alpha (IFN-α) entered clinical 
trials and was the first effective therapy for CML, being the treatment of choice for 
CML patients, before the TKIs era (46). IFN
-α is a glycoprotein of biological origin and 
displays antiviral and antiproliferative properties. This drug induces cytogenetic 
response in 35% to 55% of patients and longer survival achieved in combination with 
chemotherapy, however CML clones were rarely completely eliminated (49). 
 In 2001, FDA approves imatinib (Gleevec®) after just three months of review – 
the fastest approval in FDA history – based on data showing the drug halted the growth 
of CML clones in the most patients (40). Imatinib is the first drug proven to shut down a 
molecular “imperfection” related to a specific kind of cancer – mutation on the so-called 
“philadelphia chromosome” (40). Since, has become the care standard for CML, and its 
effectiveness and easily
-
administered pill formulation allows a relatively normal life to 
patients despite the chronic disease they carry (40). In 2006, researchers identify a 
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second targeted treatment, dasatinib (Sprycel®), for patients with chronic myelogenous 
leukemia who cannot tolerate or develop resistance to imatinib. The drug is approved 
based on reports screening that more than 90 percent of these poor prognosis patients 
had no evidence of their cancer following Dasatinib treatment (40). Dasatinib targets the 
same mutated protein as imatinib, but through a different mechanism (40) . In 2007, 
research shows that Dasatinib – initially approved for use only when treatment with 
Imatinib fails (40) – should also be an option for initial treatment of early-stage chronic 
myelogenous leukemia. The FDA approves the drug for this broader indication in 2010, 
giving CML patients more solutions (40). In 2010, two studies show that Dasatinib and 
nilotinib (Tasigna®) may be more effective than the current standard drug, Imatinib, for 
the initial treatment of chronic myeloid leukemia. These drugs target the same active 
genetic pathway on the “Philadelphia chromosome,” studies suggest that newer drugs 
possibly prompt faster and stronger responses, and less side effects than Imatinib (40). 
 
Figure 12: Clinical algorithm for CML therapy: chronic, accelerated and blast phase (50). 
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Tyrosine Kinase Inhibitor therapy 
 
 TKI based therapy is a type of targeted therapy used to treat CML. Targeted 
therapy uses drugs that target a specific or unique feature of cancer cells not generally 
present in normal cells. Because these drugs specifically target cancer cells, they may be 
less likely to harm normal cells throughout your body (45). TKIs target the abnormal 
BCR
-
ABL protein that causes the overgrowth of abnormal white blood cells (CML 
cells). The BCR
-
ABL protein belongs to tyrosine kinase proteins family located on or 
near the cell surface and control the growth and division of other cells (45). TKIs work 
in slightly different ways, but the final propose of each is inhibition of BCR
-
ABL 
protein activity (49). They are made in the form of a pill that is swallowed and the drug 
dosage is measured in mg. The FDA approved the first TKI for CML treatment in 2001 
(40). Since then, several new TKIs have been developed to treat CML. These newer 
drugs are mentioned as “second and third-generation” TKIs (45).  
 
Figure 13: Action mechanism of Imatinib. Imatinib blocks the ATP binding center of BCR-
ABL thus inhibiting its phosphorylation activity (51). 
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Imatinib 
 
 Imatinib mesylate (STI 571, Glivec®) is the most successful synthetic ATP 
inhibitor designed, first being approved by Food and Drug Administration (FDA) in the 
United States, later licensed for use in the United Kingdom by the European Medicines 
Evaluation Agency (EMEA) (40,49). Arise of Imatinib has dramatically changed the life 
style and survival of CML patients. Currently, Imatinib is considered as the “gold 
standard” in treating CML, approved for the first line treatment of adult patients at all 
disease stages (1). 
 Imatinib belongs to the “first generation” TKIs and was the first drug order to 
CML patients (49). As a mimic molecule, the drug will block the interaction between 
the tyrosine kinase and ATP, avoiding the phosphorylation of potential subtracts, thus 
Imatinib competes with ATP for the ATP
-
binding site on BCR
-
ABL protein (1,40,45). 
This mechanism decline the constitutive activity of the BCR
-
ABL protein, blocking 
some of the uncontrolled pathways characteristic of the BCR
-
ABL
+
 leukemic cells, 
furthermore decrease the metabolic features of CML (1). 
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Figure 14: Comparing the mode of action of BCR
-
ABL and Imatinib in CML 
pathogenesis. Imatinib functions as a mimic of ATP, in the ATP binding pocket in the BCR
-
ABL SH1 domain. A further characteristic of Imatinib is its striking degree of specificity for the 
ATP binding pocket, as its effect on other cellular tyrosine kinases is negligible (46). 
 
Imatinib Resistance 
 
 Although the remarkable efficacy of Imatinib in treating CML, a minority of 
patients do not respond to the therapy at all or in some cases the patients develop 
resistance to the drug. This involves the occurrence of resistant leukemic clones after 
continued drug therapy. Commonly, acquired resistance is caused most by mutations in 
the BCR
-
ABL kinase domain, preventing successfully Imatinib binding (49,51). Other 
resistance mechanisms could occur, outside the domain, like over expression of BCR
-
ABL gene, acquired additional mutations, clonal evolution (chromosomal aberrations), 
and pharmacological mechanisms. These kind of structural or biochemical 
modifications affect, direct or indirectly, the linkage between the drug and the kinase 
domain, reducing the Imatinib effect in the mutated cells (49). 
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2
nd
 and 3
RD
 Generation Tyrosine-Kinase Inhibitors 
 
 With the new highlights in target therapies the Imatinib became the support for 
CML treatment (52). Despite the really good results obtained some patients discontinue 
therapy in long
-
term due to failure and or intolerance (52). In order to overcome these 
limitations new drugs emerged, second and third
-
generation TKIs. 
 Second
-
generation TKIs are like an upgrade of the first generation TKIs, they 
are similar but the new ones have expanded inhibition against a broad spectrum of 
mutations resistance to Imatinib. Nilotinib (AMN107, Tasigna®), Dasatinib (BMS
-
354825, Sprycel®) and Bosutinib (SKI
-
606, Bosulif®) have demonstrated in vitro and 
in vivo activity against different types of mutations and various forms of resistance (52). 
However, some patients carry the T3151 mutation and don’t obtain better results with 
these drugs, but a third generation inhibitor ponatinib (AP24534, Iclusig®) was tested 
and hopeful results (52). 
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Natural Killer Cells & CML 
 
 Chronic myeloid leukemia is a slowly progressing blood and bone marrow 
disease that usually occurs during or after middle age, and rarely occurs in children. 
CML is a genetic disease that affects most directly the myeloid lineage, an abrupt 
increase in granulocytes is a hall mark for this specific leukemia (51). The NK cells 
belong to the lymphoid blood lineage and although the higher percentage of autologous 
NK cells in chronic phase CML are not derived from the malignant clone, some studies 
report that NK cells are reduced in numbers and have limited cytolytic capacity. NK cell 
function in untreated patients with chronic phase CML has not been systematically 
addressed (53). 
 Furthermore, treatment with TKIs may have additional effects on cellular 
immune function. Tyrosine kinase receptors are involved in multiple cellular processes 
and are critical in tumor development and progression (52). Recent observations 
indicated that TKIs have inhibitory and/or stimulatory effects on immune cells, via 
modification of markers in surface of tumor cells (1). Some reports focused on NK Cells 
show that Imatinib have no impact on NK cytotoxicity or cytokine production, whereas 
nilotinib negatively influenced cytokine production and Dasatinib additionally 
abrogated cytotoxicity in vitro (52,53). 
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Table 1: Overview on the impact of TKI agents on NK cells (43,52,54,55). 
TKIs 
Imatinib 
 
 DC stimulation leading to increased NK cell activity in human and 
mice. 
 Increased NK cell numbers post therapy. 
 
Nilotinib 
 
 No impact on cytotoxicity and cytokine production in vitro. 
Dasatinib 
 
 Inhibition of cytotoxicity in mice. 
 Inhibition of cytotoxicity toward K562 and cytokine production. 
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Immunotherapy 
 
 Understanding how the immune system affects cancer development and progression has 
been one of the most challenging questions in immunology. Now appreciate that the immune 
system plays a dual role in cancer: It can not only suppress tumor growth by destroying cancer 
cells or inhibiting their outgrowth but also promote tumor progression either by selecting for 
tumor cells that are more fit to survive in an immunocompetent host or by establishing 
conditions within the tumor microenvironment that facilitate tumor outgrowth (24,56). In the 
last decades researchers have reported that cancer development and progression is 
highly affected by the host immune system through a process termed cancer 
immunoediting (56). Cancer immunoediting is a three
-
step strategy that consists in 
elimination (host immune cells destroy immune cells), equilibrium (residual tumors 
persist but their growth is under control of host immunity) and escape (outgrowth of 
tumor cells with reduced immunogenicity and/or increased capacity to attenuate or 
subvert host immunity) (24,56). Based on this the immune system starts to be a 
powerful target for tumor elimination. 
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Figure 15: Cancer immunoediting: host protective versus tumor sculpting actions of 
immunity. Following cellular transformation and the failure of intrinsic tumor suppressor 
mechanisms, a developing tumor is detected by the immune system and its ultimate fate is 
determined by whether or not it is eliminated by the host protective actions of immunity 
(Elimination phase), maintained in a dormant or equilibrium state (Equilibrium phase) or 
escapes the extrinsic tumor suppressor actions of immunity by either becoming non
-
immunogenic or through the elaboration of immunosuppressive molecules and cells (Escape 
phase) (24).  
 
 The immunotherapy principle lies on stimulate and/or restore our immune 
defenses, in general these science fall into major fields, antigen
-
targeted immunotherapy 
and immunomodulatory immunotherapy (57). In antigen
-
targeted immunotherapy, 
tumor
-
associated antigens are introduced into the patient as a vaccine to elicit an 
immune response that targets the tumor. In immunomodulatory immunotherapy, the 
immune system, presumably primed by endogenous tumor
-
associated antigens, is 
potentiated either by blocking inhibitory immune effectors or by triggering immune 
activators. Both strategies qualify immune cells to become activated and target the 
tumor (57). 
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Focus on NK Cells 
 
 As long as the immune system emerged as a source of many hopes for cancer 
treatment, the researchers had focused their attention in immune cells self
-
defense 
mechanisms, especially and more recently in NK Cells (56). NK cell immunotherapy is 
rapidly developing since simple methodologies like manipulation of NK cell activity 
using antibodies or interleukins, or more complex tasks like engineering gene
-
modified 
NK Cells (37).  
Modulation of NK cell activity 
 
Antibodies – Use of antibodies to block inhibitory receptors can mimic the 
missing self
-
environment, in order to augment NK cell cytotoxicity. Recently, the 
development of human monoclonal antibodies that prevent signaling via KIR2DL1, 
KIR2DL2 and KIR2DL3 was developed, monoclonal antibody 1
-
7F9 cross
-
reacts with 
KIR2DL1, KIR2DL2 and KIR2DL3 to increase NK cell
-
mediated lysis of tumors 
expressing HLA
-
C (37). 
 
Interleukins – Il-2 activation of NK cells can promote cytotoxic activity against 
targets that were previously NK cell resistant. NK cell co
-
cultured with fresh tumor cells 
have also proved that IL
-
2 activation in vitro enhances the killing potential of NK cells. 
Il
-
15 is another promising subject for immunotherapy, as it provides NK cells, CD8+ T 
cells and NKT cells activation (37). 
 
NK cell Adoptive Therapy – NK cells can be isolated, expanded or produced in 
vitro to be used either in autologous or an allogeneic setting. It is clear that short
-
term 
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activation is not sufficient for increase NK cell count or NK cell cytotoxicity, but a long
-
term infusion of ex vivo activated cells may present a benefit (37). 
 
Gene modification of NK cells – Genetically modified NK cells hold great 
potential for cancer immunotherapy. Certain tumors, such as carcinomas lacking MHC 
class I, are resistant to NK cell killing. Hence, different methodologies have been 
developed to modify genetically these immune cells (37). 
 
 
 
Figure 16: Strategies to modulate the NK cell activity and augment their anti
-
tumor effect. 
AR, activating receptors; IR, inhibitory receptors; DC, dendritic cell; IL, interleukin; Treg, T 
regulatory cell (58). 
  
Aims 
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Aim of Research  
 
NK killer cells are innate lymphocytes capable of mediating multiple 
effector functions. NK cells express a number of receptors through which they can 
recognize microbial products, can sense transformed cells or even mediate 
regulatory functions by cytokine release. Specialized NK subsets display distinct 
functions according to their typical cell surface phenotype. Namely, the 
CD56
bright
CD16
-
 NK cell subset that present a more regulatory character and the 
CD56
dim
CD16+ NK cell subset that displays cytotoxicity and also cytokine 
production in response to stimuli. In the last decade several studies have been done 
in order to understand the immunobiology of these cells and several studies indicate 
that NK cells have an important role in immune response (59). In chronic diseases 
like CML the immune response is impaired and NK cell dysfunction could also 
affect the immune system. In addition, a variety of reports have shown that chronic 
infections and some types of cancer negatively affect the NK cell function (26,59). 
With this entire brand new knowledge, the importance of understand NK 
cells have been drastically increased. In the context of our project some researchers 
reported that NK cells are reduced in CML patients and other ones demonstrated 
that the dosage and the type of TKI could directly or indirectly affect NK cells 
(1,52,53). Thus, characterize the NK cells of CML patients is the main goal of our 
study, in order to understand how these cells behave and how we can modulate its 
activity in order to increase the effectiveness of therapies that are in vogue today 
for CML. To achieve this complex goal we focused our report on three objectives: 
study the immunoprofile of CML patients NK cells; study the effects of different 
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TKIs at different doses; study the role of BCR
-
ABL
+
 leukemic cells in NK cells 
populations.  
  
 
Chapter II – Material and Methods 
  
  
Material & Methods 
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Object of study 
 
All samples used in this research were collected in heparin tubes from Chronic Myeloid 
Leukemia patients (n=62) at Centro Hospitalar e Universitário de Coimbra for further blood 
samples analysis at the Laboratório de Imunologia e Oncologia, Centro de Neurociências e 
Biologia Celular, Universidade de Coimbra. The patients concerned are being treated with 
different drugs (Imatinib n=40, Dasatinib n=6, Ponatinib n=1) and within who are taking 
Imatinib dosing also varies (400mg/day n=17, 600mg/day n=10 and 800mg/day n=13), besides 
that some of them are taking combination therapy (IFN
-α + Imatinib 400/600mg/day n=5) or 
only IFN
-α (n=4) or Cytarabine (Ara C, cytosine arabinoside; n=1). We also have the chance to 
include in this study two naive patients, some patient’s therapy is unknown. 
This study was previously approved by Ethnics Committee of the Faculty of Medicine 
of the University of Coimbra.  
Sample Handling 
 
The samples were all treated equally, 100uL of whole blood in was taken in cytometry 
tube and extracellular antibodies were added, then 15 minutes incubation in the dark at room 
temperature. After incubation 2mL of BD Lysis buffer was added, the tubes were vortex and 
incubated for more 10 minutes in the same conditions. Following the tubes were centrifuged at 
314g for 5 minutes, supernatant was discarded and 2mL of PBS 1x was added and next tubes 
were centrifuged in the same way. The final steps before the tubes are taken to the flow 
cytometry was to discard the supernatant and add 300uL of PBS 1x. In case of intracellular 
labelling the protocol is similar, but the intracellular antibodies were only added after fix and 
permeabilize the cellular membranes with two unlike solutions. Then tubes were incubated in 
the dark for 20 minutes. After incubation 2mL of PBS 1x was added and the following steps are 
identical to the extracellular labeling protocol. The lymphogram were performed in the same 
way for extracellular labelling, except the volume of blood 50uL instead of 100uL and the 
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Lymphogram™ kit from Cytognos S.L was used., a 3-color mixture of monoclonal antibodies to 
determine the major lymphocyte subpopulations, including total T
-
cells (CD3+), B
-
cells 
(CD19+) and NK
-
cells (CD3
-
 CD56+) as well as helper/inducer (CD3+ CD4+) and 
suppressor/cytotoxic (CD3+ CD8+) T
-
cell subsets. 
Flow Cytometry Analysis 
 
All the samples were performed according to type of labelling, after that all marked 
tubes were read and analyzed on flow cytometer – FACS CANTO II from BD Biosciences with 
FACS Diva software version 6.1.3. A panel of fluorochrome
-
labeled antibodies was used in 
order to identify and characterize specific NK cell subsets. This panel includes CD3
-
PB (clone 
UCHT1), CD3
-
PerCP/Cy5.5 (clone HIT3a), CD14
-
PerCP/Cy5.5 (clone M5E2), CD19 
PerCP/Cy5.5 (clone HIB19), CD56
-
PE/Cy7 (clone HCD56) and CD16
-
APC/Cy7 (clone 3G8) 
which allowed specific NK cell subset identification. A combination of monoclonal antibodies 
was selected for characterization as follows: CD4
-
V500 (clone RPA
-
T4), CD8
-
APC (clone 
HIT8a), CD8
-
APC/Cy7 (clone SK1), CD7
-
PE (clone CD7
-
6B7), CD57
-
PB (clone HCD57), 
CD27
-
FITC (clone O323) , CD11b
-
PB (clone ICRF44), CD62L
-
FITC (clone DREG
-
56), CD69
-
FITC (clone FN50), CD137
-
APC (clone 4B4
-
1), CD137L
-
PE (clone C65
-
485),CD94
-
FITC 
(clone DX22), NKp46
-
PE (clone 9E2), NKp44
-
PE (clone P44
-
8), NKp30
-
PE (P30
-
15), NKp80
-
PE (clone 5D12), NKG2A
-
PE (clone 16A11), NKG2C
-
PE (clone 134591), NKG2C
-
APC (clone 
134591),  CD158a
-
PE (clone HP
-
MA4), CD158b
-
PE (clone DX27), IFN
-γ-FITC (clone 4S.B3), 
TGF
-β-FITC (clone TW4-6H10) and IL-4-FITC (clone 8D4-8), IL-10-FITC (clone JES3-9D7), 
TNF
-α-PE (clone MAb11), 1F12-FITC (clone 1F12H7A2), 8C11-FITC (clone 8C11F11D4), 
CD279
-
APC (clone MIH4), CD274
-
FITC (clone MIH18), CD273
-
PE (clone MIH18), CD226
-
FITC (clone TX24), CD96
-
PE (clone NK92,39), CD155
-
PE (clone TX24) and TIGIT
-
APC 
(clone IgG2B). All antibodies used were purchased from Biolegend (San Jose, CA, USA). 
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Data Analysis 
 
FlowJo® (Tree Star Inc, Ashland, USA) is powerful software that allows 
analyzing flow cytometry data on a computer. In the present study the FlowJo version 
10 was used, with this software all the samples added to the “Worksheet” frame were 
hierarchical organized and analyzed according to their lineage and surface or 
intracellular markers.  
Statistical Analysis 
 
GraphPad Prism® is commercial scientific 2D graphing and statistics software 
published by GraphPad Software, Inc (CA, USA). This informatics program combines 
scientific graphing, comprehensive curve fitting (nonlinear regression) understandable 
statistics, and data organization. All the statistical analysis was performed by GraphPad 
Prism version 6 using one
-
way or two
-
way ANOVA with Dum or Bonferroni posttests, 
respectively. Statistically significant þ
-
values are addressed as follows: * P<0.05, ** 
P<0, 01, *** P<0.001 and **** P<0.0001. 
  
 
Chapter III – Results 
 
  
Results 
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Lymphocytes and their subpopulations in CML   
 
To elucidate about the relative frequencies of lymphocytes major populations in 
CML patients, blood samples were analyzed by flow cytometry. For cellular labelling a 
Lymphogram kit was used in order to identify and calculate the percentage of B cells, T 
cells and NK cells as well as CD4+ and CD8+ cells. The lymphogram kit is a 
combination of 5 antibodies in 3 different fluorescences, CD3/CD56 –FITC, CD19/CD8 
– PE and CD4 – PerCPCy.5. First, total lymphocytes were selected according to SSC 
and FSC know characteristics (figure 17.A). After total lymphocytes selection, B cells, 
T cells and NK cells were distinguished based on, respectively, CD19, CD3 and CD56. 
These three markers are specific for its population (figure 17.B).  Then, within T and 
NK cells we selected the CD4 and CD8 positive cells (figure 17.C/D). 
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Figure 17: Representative gating strategy. A – Representative dot plots of total lymphocytes; 
B – Representative dot plots of B cells, T cells and NK cells; C – Representative zebra plot of 
CD4 and CD8 positive cells on NK cells; D – Representative zebra plot of CD4 and CD8 
positive cells on T cells.   
 
Fifty
-
five blood samples (four from healthy donors, two from naïve CML and forty
-
nine 
from treated CML) were analyzed by flow cytometry and then the relative frequencies 
of each cell type was calculated by FlowJo software. Representative graphs were made 
by GraphPad software.  
Relative frequency of total lymphocytes is decreased in CML patients. 
 
Patients on therapy have higher percentage of lymphocytes than at diagnosis, 
however didn’t achieve the values of lymphocytes from healthy donors (figure 18.A). 
However the amount of lymphocytes/µL collected from CML patients on treatment is 
decreased in comparison with those collected at diagnosis (figure 18.B).   
A B 
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Figure 18: Relative frequencies of lymphocytes in CML patients. A – Percentage of 
lymphocytes from PBMCs in healthy donors (n=4), naïve (n=2) and CML patients (n=49). B – 
Absolute numbers of lymphocytes in peripheral blood of naïve (n=2) and CML patients (n=20). 
C – Analysis of lymphocytes major populations, B cells, T cells and NK cells from PBMCs of 
healthy donors (n=4), naive (n=2) and CML patients (n=38). D – B cells, T cells and NK cells 
absolute numbers in healthy donors (n=4) and CML patients (n=20). 
  
Relative frequency of T, B and NK cells at diagnosis is lower than in healthy 
individuals. 
 
 After gating the lymphocytes population with the combination of antibodies 
used allows separate the three big families of lymphocytes. B cells (CD19+CD3
-
CD56
-
), T cells (CD3+CD56
-
CD19
-
) and NK cells (CD56+CD3
-
CD19
-
) are selected based on 
density of their specific markers. The 3 cell types are reduced in blood samples 
collected at diagnosis and with therapy these values recover to normal  standards, 
according to controls (figure: 18.C). Individuals who are receiving treatment appear to 
have a higher percentage of NK cells in relation to the amount of total lymphocytes; 
however the absolute numbers of NK cells from CML patients are lower than NK cells 
from healthy donors on average (figure 18.D). The absolute numbers of CML B cells 
A B 
C D 
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are lightly higher than from controls and the CML T cells are drastically reduced (figure 
18.D).   
CD4 and CD8 expression on T and NK cells surface is altered in naïve and CML 
patients. 
 
With the populations of interest rightly identified another parameters were 
analyzed. The combination of Abs in the lymphogram kit has CD4 and CD8 besides the 
specific markers, allowing the study of CD4 and CD8 positive cells contribution. In 
naïve T
-
Lymphocytes the CD4+ subpopulation is decreased in terms of lymphocyte 
percentage (figure 19.A). Although the CD8 subset of individual without treatment is 
increased relatively to controls and in individuals undergoing treatment this percentage 
decrease to normal values (figure 20.A), the absolute numbers of CD4+ and CD8+ T 
cells from CML patients are lower than those from naïve (figure 19.B). Moreover CML 
patients have a huge decrease in CD8+ T cells with statistically significance. 
In NK cells from CML patients the percentage of CD4 positive cells is decreased but its 
absolute numbers are enlarged at diagnosis, after treatment these values tend to decrease 
to minimal levels (figure 19.C/D). The percentage of CD8+ NK cells is reduced at 
diagnosis and it is augmented in treated patients, yet CD8+ NK cells absolute numbers 
are 
dim
inished in treated CML cells (figure 19.C/D). 
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Figure 19: Relative frequencies of CD4+ and CD8+ in lymphocytes and NK cells. A – 
Frequencies of CD4+ and CD8+ T
-
Lymphocytes. B – Absolute numbers of CD4+ and CD8+ T- 
Lymphocytes in peripheral blood. C – Frequencies of CD4+ and CD8+ NK cells. D – Absolute 
numbers of CD4+ and CD8+ T
-
 NK cells in peripheral blood. Controls (n=4); Naïve CML 
(n=2); Treated CML (n=34). 
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Immunoprofiling of NK cells from CML patients   
 
CD56
bright
CD16+ and CD56
dim
CD16+ NK cells are until now the two more 
distinct subsets of NK cells. Based on this and in the previous knowledge about their 
intrinsic functionalities whole this study is developed around CD56
bright
 and CD56
dim
 
cells rather than looking at the overall NK cells.  
All the experiments are performed at the same way as explained in the chapter 
before. After load the samples in cytometer data results are analyzed by informatics 
software (FlowJo), at the early beginning the gating strategy is the same (figure 20). 
First of all lymphocytes are selected based on forward/scattered properties, and then the 
gated population is displayed in a CD56/ (CD3CD14CD19) plot which avoid NK cell 
identification (CD56+ (CD3CD14CD19)
-
). Identified NK cells are divided in 
CD56brigh and CD16
dim
 NK cells according to their expression of CD56 and CD16.  
 
 
 
Figure 20: Gating strategy for CD56brighCD16- and CD56dimCD16+ NK cells from CML 
patients. From left to right, representative dot plot of lymphocytes, next representative 
zebraplot of NK cells followed by representative zebraplot of CD56
bright
CD16
-
 and 
CD56
dim
CD16+ NK cells.  
 
NK cells are increased in CML patients undergoing treatment. 
 
 NK cells from healthy donors are 6.1% of lymphocytes on average and NK cells 
from naïve patients (which mean that the samples are collected at diagnosis) represent a 
similar rate. Treated CML patients have a relative increase on NK cells percentage, 
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although without statistical significance (figure 21.A). Besides that NK cell absolute 
count increase from healthy donors to naïve patients and then with the higher rate the 
treated patients (figure 21.B).  
The proportion of CD56
bright
CD16
-
 and CD56
dim
CD16+ NK cells is independent of 
the disease. 
 
In healthy donors, naïve and in CML patients the relative frequency of the 
CD56brigh and CD56
dim
 cells doesn’t significantly change. The CDbrightCD16- subset 
represents around 7% of total NK cells whiling the CD56
dim
CD16+ subset represents 
around 90% in all three groups (figure 21.C). 
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Figure 21: Relative proportions of NK cells and their subpopulations. A – NK cells 
percentage from all lymphocytes in healthy donors (controls), naïve and CML patients based on 
positive selection for CD56 marker and negative selection for CD3 marker. B – NK cells 
A B 
C 
Characterization of Natural Killer Cells in Chronic Myeloid Leukemia Patients 
55 
absolute count to each group. C
-
 CD56
bright
CD16
-
 and CD56
dim
CD16+ NK cells percentage also 
for each group. Controls (n=4); naïve (n=2); treated CML (n=49).   
 
 Surface markers, receptors and cytokine production are crucial factors for 
effectiveness of NK cells. In CML patients some reports show that NK cells are affected 
by leukemic cells in this line we selected a few markers of interest in order to address 
some alterations in CML patients that could be involved with the low activity of NK 
cells against leukemic cells in some patients.  
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Expression of cell surface markers by CD56brightCD16- and CD56dimCD16+ NK 
cells in CML patients 
 
After CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells identification we analyzed 
other parameters. With extracellular labelling for multiparametric flow cytometry a 
variety of markers can be evaluated simultaneously, so information about cell surface 
markers is provided. The frequency of positive labelling for CD4, CD8, CD7, CD57, 
CD27, CD11b CD62L and CD69 were studied and analyzed by informatics software 
described on chapter II (figure 22). The samples were divided into the same 3 groups as 
previous, healthy donors (controls), naïve (naïve CML) and CML patients (treated 
CML). 
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Figure 22: Expression of cell surface markers on CD56brighCD16
-
 and CD56dimCD16+ 
NK cells, from CML patients. A – Representative zebraplots of positive labelling of CD4, 
CD8, CD7 and CD57, CD27, CD11b, CD62L and CD69 in CD56
bright
CD16
-
 NK cells (up to 
down). B
-
 Representative zebraplots of positive labelling of same markers in CD56
dim
CD16+ 
NK cells.   
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 After CD56
bright
CD16
-
 and CD56
dim
CD16+ NK cells identification we analyzed 
other parameters. With extracellular labelling for multiparametric flow cytometry a 
variety of markers can be evaluated simultaneously, so information about cell surface 
markers is provided. The frequency of positive labelling for CD4, CD8, CD7, CD57, 
CD27, CD11b CD62L and CD69 were studied and analyzed by informatics software 
described on chapter II (figure 22). The samples were divided into the same 3 groups as 
previous, healthy donors (controls), naïve (naïve CML) and CML patients (treated 
CML).  
Relative frequency of CD4
+
CD56
bright
CD16
-
 NK cells is reduced in CML patients 
and the percentage of CD8
+
 CD56
bright
CD16
-
 NK cells is higher in CML patients. 
 
 CD4+ CD56
bright
CD16
-
 cells are null in naïve patients and in those who 
undergoing treatment is a little higher but even so don’t achieve healthy donors 
percentage (figure 23A). The MFI results displayed higher fluorescence in cells from 
naïve and CML patients than for controls both in CD56
bright
 and CD56
dim
 NK cells 
(figure 23.B). CD8+ CD56
bright
CD16
-
 NK cells percentage is augmented in naïve and 
CML patients, being the higher percentage in patients doing therapy. The 
CD8+CD56
dim
CD16+ NK cells percentage is diminished at diagnosis, but in patients 
under therapy this values reach near controls values (figure 23.C). The MFI for both 
CD8+ NK cells subsets is increased in CML patients and there not much difference 
between the values for the controls and naïve (figure 23.D). 
 
Characterization of Natural Killer Cells in Chronic Myeloid Leukemia Patients 
60 
CD56bright CD16- CD56dim CD16+
0
2
4
6
8
10
Controls
Naive CML
Treated CML
nsnsnsns
nsns
C
D
4
+
 N
K
 C
e
ll
s 
%
CD56bright CD16- CD56dim CD16+
0
100
200
300
Controls
Naive CML
Treated CML
ns ns
nsns nsns
C
D
4
+
 M
FI
CD56bright CD16- CD56dim CD16+
0
20
40
60
80
Controls
Naive CML
Treated CML
nsns
nsns nsns
C
D
8
+
 N
K
 C
e
ll
s 
%
CD56bright CD16- CD56dim CD16+
0
1000
2000
3000
Controls
Naive CML
Treated CML
nsns
nsns nsns
C
D
8
+
 M
F
I
 
Figure 23: Percentage of CD4+ and CD8+ CD56brightCD16
-
 NK cells and of CD4+ and 
CD8+ CD56dimCD16+ NK cells from healthy donors (n=4), naïve (n=2) and CML patients 
(n=41). A – Percentage of CD4+ CD56brightCD16- NK cells and CD4+ CD56dimCD16+ NK 
cells. B – Mean of fluorescence intensity of CD4 in CD56bright and CD56dim populations. C – 
Percentage of CD8+ CD56
bright
CD16
-
 NK cells and CD8+ CD56
dim
CD16+ NK cells. D – Mean 
of fluorescence intensity of CD4 in CD56
bright
 and CD56
dim
 populations.  
 
CD56
bright
CD16
-
 NK cells from CML patients have a higher expression of CD7 per 
cell and CD56
dim
CD16+ NK cells from naïve patients have a higher expression of 
CD57 per cell, in comparison with healthy controls. 
 
With the same strategy as before lymphocyte population is gated, NK cells are 
identified and then the CD7 and CD57 positive cells are calculated. The percentage of 
CD7+ cells within CD56
bright
 and CD56
dim
 population approximated for healthy 
controls, naïve and CML patients (figure 24.A). However, the MFI for CD7 in 
CD56
bright
CD16
-
 NK cells is quite elevated, with statistically significance (figure 24.B). 
The MFI provides information about the fluorescence intensity, as the name says, of 
certain parameters (markers added to the samples) giving us an idea about the density of 
each marker per cell, so in this case the surface expression of CD7 by CD56
bright
CD16
-
NK cells from CML patients is highly increased. Healthy donors have a very low 
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percentage of CD57+ CD56
bright
CD16
-
 NK cells (~2%), the same population in naïve 
and CML patients is relatively higher (~5%) (figure 24.C). The MFI for CD57 in 
CD56
bright
 subset is null for the three groups and the MFI of CD57 in CD56
dim
 subset is 
drastically increased in naïve group, CML patients have much lower MFI values 
although greater then healthy donors (figure 24.D). 
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Figure 24: Percentage of CD7+ and CD57+ CD56brightCD16
-
 NK cells and of CD7+ and 
CD57+ CD56dimCD16+ NK cells from healthy donors (n=4), naïve (n=2) and CML 
patients (n=20). A – Percentage of CD7+ CD56brightCD16- NK cells and CD7+ CD56dimCD16+ 
NK cells. B – Mean of fluorescence intensity of CD7 in CD56bright and CD56dim populations. C – 
Percentage of CD57+ CD56
bright
CD16
-
 NK cells and CD57+ CD56
dim
CD16+ NK cells. D – 
Mean of fluorescence intensity of CD57 in CD56
bright
 and CD56
dim
 populations.  
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CML patients NK cells have higher expression of CD27 in CD56
bright
cd16
-
 subset. 
The percentage of CD11b+ NK cells is augmented in CD56
bright
 subset of CML 
patients and the surface density of CD11b is higher in both CD56brigh and 
CD56
dim
 NK cells.     
 
For these two markers only two groups of individuals are taking in account, 
healthy donors (controls) and CML patients (treated CML), samples of naïve patients 
were not available. The percentage of CD27 positive cells in CD56
bright
CD16+ 
population don’t vary from group to group so as in CD56dimCD16- population (figure 
25.A). The CD27 MFI is much more superior for CD56
bright
CD16
-
 NK cells from CML 
patients (with statistical significance); regarding CD56
dim
CD16+ NK cells the values are 
similar (figure 25.B). The percentage of CD11b+ cells is higher in the CD56
bright
 subset 
from CML patients (with statistical significance), with respect to CD56
dim
 subset there 
is no relevant difference (figure 25.C). Relative to CD11b MFIs for both NK subsets 
there is an increased in CML patients comparing with controls (figure 25.D). 
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 Figure 25: Percentage of CD27+ and CD11b+ CD56brightCD16
-
 NK cells and of 
CD27+ and CD11b+ CD56dimCD16+ NK cells from healthy donors (n=4) and CML 
patients (n=33). A – Percentage of CD27+ CD56brightCD16- NK cells and CD27+ 
CD56
dim
CD16+ NK cells. B – Mean of fluorescence intensity of CD27 in CD56bright and 
CD56
dim
 populations. C – Percentage of CD11b+ CD56brightCD16- NK cells and CD11b+ 
CD56
dim
CD16+ NK cells. D – Mean of fluorescence intensity of CD11b in CD56bright and 
CD56
dim
 populations. 
 
In CD56
bright
CD16
-
 NK cells, the percentage of CD62L+ and CD69
+
 cells and their 
surface density is augmented in CML patients. 
 
As we can see in figure below (figure 26.A) the percentage of CD62L positive 
cells is augmented in both CD56
bright
 and CD56
dim
 NK cells, notably in CD56
bright
 subset 
this percentage increase drastically, with statistically significance. The CD62L MFI is 
also much higher for CD56
bright
 subset of CML patients (with statistically significance), 
for CD56
dim
 subset the advantage for CML patients is tenuous (figure 26.B). For CD69 
positive cells, the two subsets behave differently. CD69
+
CD56brigh cells reveal lower 
percentages of CD69
+
 cells in healthy donors, at diagnosis an increase is notice and 
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CML patients achieve  the highest values (figure 26.C), with statistically significance. 
In terms of CD69 MFI measurements, CML cells have higher intensities in both 
subpopulations (figure 26.D). 
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Figure 26: Percentage of CD62L+ and CD69+ CD56brightCD16- NK cells and of CD62L+ 
and CD69+ CD56dimCD16+ NK cells from healthy donors, naïve and CML patients. A – 
Percentage of CD7
+
 CD56
bright
CD16
-
 NK cells and CD7
+
 CD56
dim
CD16
+
 NK cells. B – Mean of 
fluorescence intensity of CD7 in CD56
bright
 and CD56
dim
 populations. C – Percentage of CD57+ 
CD56
bright
CD16
-
 NK cells and CD57
+
 CD56
dim
CD16
+
 NK cells. D – Mean of fluorescence 
intensity of CD57 in CD56
bright
 and CD56
dim
 populations. For CD62L samples are collected 
from healthy donors (n=4) and CML patients (n=43). For CD69 samples are collected from 
healthy donors (n=12), naïve (n=1) and CML patients (n=30). 
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The surface density of CD137L and CD137 and the CD137
+
 cell percentage is 
augmented in both CD56
bright
 and CD56
dim
 NK cells from CML patients. 
 
The CD137L
+
 cells percentage within the two NK subpopulations is similar from 
healthy to CML individuals, but the naïve samples have lower percentages of 
CD137L
+
CD56
bright
CD16
-
 NK cells (figure 27.A). CD137L MFI increases in naïve and in CML 
individuals, those who are undergoing treatment have the highest number (figure 27.B). The 
percentage number of CD137
+
 CD56brigh and CD56
dim
 NK cells is augmented in CML 
patients, more in 
bright
 then in 
dim
 subset (figure 27.C). The MFI value for CD137 in the same 
populations is higher for CML patients (figure 27.D). 
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Figure 27: Percentage of CD137L+ and CD137+ CD56brightCD16- NK cells and of 
CD137L+ and CD137+ CD56dimCD16+ NK cells. From healthy donors (n=4), naïve (n=2) 
and CML patients (n=20). A – Percentage of CD137L+ CD56brightCD16- NK cells and 
CD137L+ CD56dimCD16+ NK cells. B – Mean of fluorescence intensity of CD137L in 
CD56
bright
 and CD56
dim
 populations. C – Percentage of CD137+ CD56brightCD16- NK cells and 
CD137
+
 CD56
dim
CD16
+
 NK cells. D – Mean of fluorescence intensity of CD137 in CD56bright 
and CD56
dim
 populations.  
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The ratio CD137/CD137L in CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells is 
augmented in CML patients. 
 
By statistical analysis performed by GraphPad Prism we calculated the ratio 
CD137
+
CD56
bright
CD16
-
/CD137L
+
CD56
bright
CD16
-
 NK cells and the ratio 
CD137
+
CD56
dim
CD16
+
/CD137LCD56
dim
CD16
+
 NK cells from both healthy donors and CML 
patients. The results show that CML patients have an increase in both ratios (figure 28).  
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Figure 28: CD137/CD137L ratio in CD56brightCD16- NK cells and in CD56dimCD16+ 
NK cells, from healthy donors (n=4) and CML patients (n=20).  
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Receptor repertoire of CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells from healthy 
donors and CML patients 
 
 To access information about the receptors expressed by NK cells the same 
procedure was performed, changing only the surface markers. This study allows us to 
identify differences in the receptor repertoire of NK cells between healthy controls and 
CML patients, so in this context we measure by flow cytometry the expression of some 
KIRs (KIR2DL1, KIR2DL2 and KIR2DS1), C
-
type lectin
-
like receptors (NKG2 family  
and NKp80), and NCRs (NKp30, NKp44, and NKp46). 
KIR2DL1, KIR2DL2 and KIR2DS1 expression is altered in CML patients. 
 
 The percentage of KIR2DL1, KIR2DL2 and KIR2DS1 is measured by the 
combination of four markers/Abs CD158a, CD158b, 8C11 and 1F12 as described in 
(60) and the results that allows us calculate de percentage number of KIRs are in the 
appendix (figure 29). 
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Figure 29: Representative zebraplots of KIR2DS1, KIR2DL1 and KIR2DL2 expression on 
CD56brightCD16- and CD56dimCD16+ NK cells from CML patients. Multiparametric 
analysis of CD158a, CD158b, 8C11 and 1F12 markers. 
 
 The expression of KIR2DL1 by CD56
bright
CD16
-
 NK cells is drastically 
decreased (with statistical difference) in CML patients, whereas in CD56
dim
CD16
+
 NK 
cells the KIR2DL1 expression doesn’t vary significantly (figure 30.A). KIR2DS1 
expression by CD56
bright
 cells is decrease and by CD56
dim
 cells is increased in CML 
patients comparing with controls (figure 30.B). KIR2DL2 expression is higher in CML 
patients than in healthy individuals for both NK cells subsets (figure 30.C).  
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Figure 30: KIR2DL1/L2/S1 expression by CD56brightCD16- and, from healthy donors 
(n=4) and CML patients (n=10). A – KIR2DL1 expression by CD56dimCD16+ NK cells; B – 
KIR2DS1 expression by CD56
dim
CD16
+
 NK cells; C – KIR2DL2 expression by CD56dimCD16+ 
NK cells. 
 
The NKG2A expression and surface density on CD56
bright
CD16
-
 NK cells and the 
surface density of NKG2C on CD56
dim
CD16
+
 NK cells is decreased in CML 
patients. 
 
NK cells express other receptors like NKG2A and NKG2C, the NKG2A is an 
inhibitory receptor and the NKG2C is an activating receptor. In this study we access to 
their expression in CML patients (figure 31) and in healthy controls.  
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Figure 31: Representative zebraplots of NKG2A and NKG2C expression on 
CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells from CML patients. 
 
 
 The expression of NKG2A is decreased essentially in the CD56
bright
CD16
-
 NK 
cells (with statistical significance) comparing with healthy controls, in the CD56
dim
 
subpopulation the percentage of NKG2A positive cells is almost the same in both 
groups (figure 32.A). The surface density of NKG2A is drastically decreased in 
CD56
bright
CD16
-
 NK cells (with statistically significance), in the CD56
dim
CD16
-
 
subpopulation the surface expression don’t differ significantly (figure 32.B). The 
percentage of NKG2C positive cells in NK cells don’t change significantly, but in the 
CD56
bright
CD16
-
 subpopulation a relative decrease is notice and in the CD56
dim
CD16
+
 
Characterization of Natural Killer Cells in Chronic Myeloid Leukemia Patients 
71 
subpopulation the percentage of NKG2C positive cells is augmented (figure 32.C). The 
surface density of this receptor in both groups is similar in CD56
bright
CD16
-
 
subpopulation, however in the CD56
dim
CD16
+
 subpopulation the NKG2C surface 
density, in CML patients, is severely decreased ( with statistical significance) (figure 
32.D). 
 
CD56brightCD16- CD56dimCD16+
0
2000
4000
6000
8000
Controls
Treated CML
*** ns
N
K
G
2
A
+
 M
F
I
CD56brightCD16- CD56dimCD16+
0
20
40
60
80
100
Controls
Treated CML
** ns
N
K
G
2
A
+
 N
K
 C
e
ll
s 
%
CD56brightCD16- CD56dimCD16+
0
500
1000
1500
Controls
Treated CML
ns ***
N
K
G
2
C
+
 M
F
I
CD56brightCD16- CD56dimCD16+
0
10
20
30
Controls
Treated CML
nsns
N
K
G
2
C
+
 N
K
 C
e
ll
s%
 
Figure 32: Percentage of NKG2A+ and NKG2C+ CD56brightCD16- NK cells and of 
NKG2A+ and NKG2C+ CD56dimCD16+ NK cells. From healthy donors (n=4) and CML 
patients (n=10). A – Percentage of NKG2A+ CD56brightCD16- NK cells and NKG2A+ 
CD56dimCD16+ NK cells. B – Mean of fluorescence intensity of NKG2A in CD56bright and 
CD56
dim
 populations. C – Percentage of NKG2C+ CD56brightCD16- NK cells and NKG2C+ 
CD56
dim
CD16
+
 NK cells. D – Mean of fluorescence intensity of NKG2C in CD56bright and 
CD56
dim
 populations.  
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The ratio NKG2C/NKG2A is increased in CML patients, both in CD56
bright
CD16
-
 
NK cells and CD56
dim
CD16
+
 NK cells. 
 
In order to identify significant differences in the relationship between inhibitor 
and activator receptors we study the ratio NKG2C/NKG2A, what give us an idea about 
the contribution activators/inhibitors in NK cells from CML patients and healthy 
controls. In present research we saw that in both subsets of NK cells the ratio 
NKG2C/NKG2A is increased in CML patients comparing with controls (figure 33). 
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Figure 33: NKG2C/NKG2A ratio in CD56
bright
CD16
-
 NK cells and in CD56
dim
CD16
+
 NK 
cells, from healthy donors (n=4) and CML patients (n=10).  
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NKp30, NKp44, NKp46 and NKp80 expression by NK cells in CML patients is 
different from healthy controls.  
 
The natural cytotoxic receptors are activating receptors. We analyzed the 
percentage of NKp30, NKp44, NKp46 and NKp80 in CML patients and we noticed 
that, with exception for NKp44, the other receptors are more expressed by the cytotoxic 
NK cells, CD56
bright
CD16
-
 subpopulation (figure 34).   
 
 
Figure 34: Representative zebraplots of NKp30, NKp44, NKp80 and NKp46 expression on 
CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells from CML patients. 
  
When we compared the expression of the concerned receptors in CML patients 
and in healthy controls differences were observed. In CML patients the expression of 
NKp30 is slightly augmented in the CD56
bright
CD16
-
 NK cells and in the 
CD56
dim
CD16
+
 NK cells the expression of NKp30 is 
dim
inished with statistical 
significance (figure 35.A). In terms of MFI, the intensities in both NK subsets are 
comparable (figure 35.B). The expression of NKp44 in CML patients is reduced in 
CD56
bright
 NK cells and augmented in CD56
dim
 NK cells (figure 35.C). The MFI shows 
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us that the surface density of this receptor in the CD56
bright
 population is higher for 
patients then for healthy donors (with statistical significance), however for the CD56
dim
 
population the opposite happens (figure 35.D). In CML patients the expression of 
NKp46 is a little high for both NK subpopulations, comparing with healthy donors 
(figure 35.E). The surface density of this receptor is higher in CML patients, mainly in 
CD56
bright
CD16
-
 NK cells (with statistical significance) (figure 35F). Finally, for 
NKp80 both expression and surface density is equal in CML patients and healthy 
donors even though the MFI for CML patients is a bit high (figure 35.G/H).  
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Figure 35: Percentage of NCRs expression on CD56brightCD16- NK cells and of NCRs 
expression on CD56dimCD16+ NK cells. From healthy donors (n=4) and CML patients 
(n=10). A – Percentage of NKp30+ CD56brightCD16- NK cells and NKp30+ CD56dimCD16+ NK 
cells. B – Mean of fluorescence intensity of NKp30 in CD56bright and CD56dim populations. C – 
Percentage of NKp44
+
 CD56
bright
CD16
-
 NK cells and NKp44
+
 CD56
dim
CD16
+
 NK cells. D – 
Mean of fluorescence intensity of NKp44 in CD56
bright
 and CD56
dim
 populations. E – Percentage 
of NKp46
+
 CD56
bright
CD16
-
 NK cells and NKp46
+
 CD56
dim
CD16
+
 NK cells. F – Mean of 
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fluorescence intensity of NKp46 in CD56
bright
 and CD56
dim
 populations. G – Percentage of 
NKp80
+
 CD56
bright
CD16
-
 NK cells and NKp80
+
 CD56
dim
CD16
+
 NK cells. H – Mean of 
fluorescence intensity of NKp80 in CD56
bright
 and CD56
dim
 populations.  
 
Cytokine production by CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells from healthy 
donors, naïve and CML patients 
 
 The production and release of cytokines allows the signaling transduction 
between NK cells and other immune cells. In the current project we measure by flow 
cytometry the percentage of IFN-γ, TNF-α, TGF-β, IL-4 and IL-10 (figure 36). 
 
Figure 36: Representative zebraplots of IFN-γ, TNF-α, TGF-β, IL-4 and IL-10 positive 
cells on CD56brightCD16- and CD56dimCD16+ NK cells from CML patients. 
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The IL-4 and IL-10 production by NK cells is augmented in naïve individuals and 
reduced in CML patients, comparing with healthy donors. 
 
For interleukins, we measure the percentage of IL-4 and IL-10 positive NK cells 
of healthy donors (n=4), naïve patients (n=2) and CML patients (n=40). In the naïve 
group we can see that the percentage of both IL-4 and IL-10 is increased comparing 
with controls, and in the CML patients this percentage decrease achieving lower 
percentages then in controls, with statistical significances (figure 37.A/C). In the other 
hand the MFIs for IL-4 and IL-10 are diminished in naïve group and augmented in 
CML patients, comparing with healthy donors (figure 37.B/D). 
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Figure 37: Percentage of IL-4 and IL-10 CD56brightCD16- positive NK cells and of IL-4 
and IL-10 CD56dimCD16+ positive NK cells. From healthy donors (n=4), naïve (n=2) and 
CML patients (n=40). A – Percentage of IL-4+ CD56brightCD16- NK cells and IL-4+ 
CD56
dim
CD16
+
 NK cells. B – Mean of fluorescence intensity of IL-4 in CD56bright and CD56dim 
populations. C – Percentage of IL-10+ CD56brightCD16- NK cells and IL-10+ CD56dimCD16+ NK 
cells. D – Mean of fluorescence intensity of IL-10 in CD56bright and CD56dim populations. 
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NK cells production of TGF-β, TNF-α and IFN-γ is affected by the disease. 
 
Using the same procedure we measure the percentage of other cytokines present 
in NK cells. For TGF-β and TNF-α we don’t have chance to study naïve individuals, so 
for these two markers we just have two groups, healthy donors and CML patients. For 
IFN-γ we study two naïve patients beyond healthy donors and CML patients. The 
percentage of positive TGF-β NK cells is drastically reduced in CML patients, with 
statistical significance (figure 38.A), in both CD56
bright
CD16
-
 and CD56
dim
CD16
+
 cells. 
However, the MFIs for this cytokine are increased in CML patients, with statistical 
significance (figure 38.B).  In CML patients the percentage of positive cells for TNF-α 
is relatively increased in both NK subsets (figure 38.C) and the same thing happens for 
the MFIs (figure 38.D). In case of IFN-γ we had the opportunity to study naïve patients 
too. Our results show that CML patients have the higher percentage of IFN-γ+ 
CD56
bright
CD16
-
 NK cells (with statistical significance), followed by the naïve group 
and the lowest value is correlated with healthy donors (figure 38. E), in the 
CD56
dim
CD16
+
 population the percentages for IFN-γ is similar. The MFI for IFN-γ is 
augmented for CML patients mainly in the CD56
bright
 subset, the IFN-γ MFIs for 
controls and naïve groups are equal (figure 38.F). 
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Figure 38: Percentage of TGF-β, TNF-α and IFN-γ CD56brightCD16- positive NK cells 
and of TGF-β, TNF-α and IFN-γ CD56dimCD16+ positive NK cells. From healthy donors 
(n=4), naïve (n=2) and CML patients (n=10 for TGF-β, n=6 for TNF-α and n=40 for IFN-γ). A 
– Percentage of TGF-β+ CD56brightCD16- NK cells and TGF-β+ CD56dimCD16+ NK cells. B 
– Mean of fluorescence intensity of TGF-β in CD56bright and CD56dim populations. C – 
Percentage of TNF-α+ CD56brightCD16- NK cells and TNF-α+ CD56dimCD16+ NK cells. D 
– Mean of fluorescence intensity of TNF-α in CD56bright and CD56dim populations. E – 
Percentage of IFN-γ+ CD56brightCD16- NK cells and IFN-γ+ CD56dimCD16+ NK cells. F – 
Mean of fluorescence intensity of IFN-γ in CD56bright and CD56dim populations.  
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Briefly research of some special markers in NK cells from CML patients 
 
 Additionally, we did a quick research about other important markers that are 
emerging as powerful targets for modulating NK cell activity. So we did a briefly 
research about the expression of DNAM-1, CD155, CD96, TIGIT, PD-1, PD-L1 and 
PD-L2 in NK cells.  
The expression and surface density of CD96, DNAM-1, CD155 and TIGIT of CML 
patients don’t differ, significantly, from healthy donors. 
 
We study the expression of CD96, DNAM-1, CD155 and TIGIT on 
CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells. For NK cells the percentage and MFI for 
the present markers in CML patients don’t change significantly comparing with controls 
(figure 39).  
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Figure 39: Percentage of CD96, DNAM-1, CD155 and TIGIT on CD56brightCD16
-
 and 
CD56dimCD16 NK cells from healthy donors (n=4) and CML patients (n=7). A – 
Percentage of CD96 positive CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells. B – Mean of 
fluorescence intensity of CD96 in CD56
bright
 and CD56
dim
 NK cells. C – Percentage of DNAM-1 
positive CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells. D – Mean of fluorescence intensity of 
DNAM-1 in CD56
bright
 and CD56
dim
 NK cells. E – Percentage of CD155 positive 
CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells. F – Mean of fluorescence intensity of CD155 in 
CD56
bright
 and CD56
dim
 NK cells. G – Percentage of TIGIT positive CD56brightCD16- and 
CD56
dim
CD16
+
 NK cells. H – Mean of fluorescence intensity of TIGIT in CD56bright and 
CD56
dim
 NK cells. 
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The expression and surface density of PD-1, PD-L1 and PD-L2 of CML patients 
don’t differ, significantly, from healthy donors. 
 
In our results we can’t see any differences in the expression or surface density of 
PD-1, PD-L1 and PD-L2 in NK cells from CML patients relatively to healthy controls 
(figure 40), with the exception for PD-1 MFI in NKT cells, with statistically 
significance (figure 40.B).   
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Figure 40: Percentage of PD-1, PD-L1 and PD-L2 on CD56brightCD16- and 
CD56dimCD16+ NK cells from healthy donors (n=4) and CML patients (n=7). A – 
Percentage of PD-1 positive CD56brightCD16
-
 and CD56dimCD16
+
 NK cells. B – Mean of 
fluorescence intensity of PD-1 in CD56bright and CD56dim NK cells. C – Percentage of PD-L1 
positive CD56brightCD16
-
 and CD56dimCD16
+
 NK cells. D – Mean of fluorescence intensity 
of PD-L1 in CD56bright and CD56dim NK cells. E – Percentage of PD-L2 positive 
CD56brightCD16
-
 and CD56dimCD16
+
 NK cells. F – Mean of fluorescence intensity of PD-L2 
in CD56bright and CD56dim NK cells. 
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Effect of CML therapies, biologic or TKI therapy, and dosage in NK cells 
 
 The major goal of this study is try to understand how NK cells are affected in 
CML patients, further that we also try to understand if those alterations in NK CML 
cells are more evidenced in patients with certain type of therapy or certain dosage. After 
all the data exported from cytometer analyzed we divided our results according to the 
therapy and the dosage. So, in general, we have seven different groups. Eighteen CML 
patients are doing Imatinib 400, eight are doing Imatinib 600, eight are doing Imatinib 
800, five are doing Dasatinib 100, one are doing ponatinib, three are doing IFN-α and 
seven are doing other therapies like Ara
-
C or combination therapy with IFN-α plus 
Imatinib 100. These data are based on the previous results for the immunoprofiling of 
NK cells in CML patients. The statistical analysis is based on comparing all the groups 
with the Imatinib 400 group, because is the standard therapy for CML patients. 
The percentage of lymphocytes is independent of therapy and dosage, but the 
percentage of NK cells differs. 
 
The percentage of total lymphocytes in CML patients is more or less the same in all 
groups, being independent of therapy and dosage (figure 41.A). Relatively to NK cells 
we saw that the Dasatinib group has the highest percentage and count, and the lowest 
percentage and count correspond to those patients that are doing ponatinib or other 
therapies, with statistical significance (figure 41.B/C). We observed to that the 
percentage and count of NK cells don’t differ significantly with the Imatinib dosage 
(figure 41.B/C). Within the NK cell population we measure the percentage of CD56
bright
 
and CD56
dim
 subsets. For the CD56
bright
CD16
-
 NK cells percentage we verified that the 
ponatinib and others group ensured the highest percentage (with statistical significance) 
and for the CD56
dim
CD16
-
 NK cells the percentage for all the groups is around 80% 
Characterization of Natural Killer Cells in Chronic Myeloid Leukemia Patients 
85 
(figure 41.D). Further that we revealed that the percentage of CD56
bright
 NK cells 
decreased in accordance with the increase in dose of Imatinib (figure 41.D). 
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Figure 41: Percentage of total lymphocytes, NK cells and NK cells subpopulations from 
CML patients according to therapy and dosage. A – Percentage of lymphocytes. B – Count 
of NK cells. C – Percentage of NK cells. D – Percentage of CD56brightCD16- and 
CD56dimCD16+ NK cells. Imatinib 400 (n=18); Imatinib 600 (n=8); Imatinib 800 (n=8); 
Dasatinib (n=5); Ponatinib (n=1); IFN-α (n=3); Others (n=7).  
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The expression of cell surface markers by CD56brightcd16- and CD56dimcd16+ 
NK cells from CML patients varies with therapy and dosage.  
 
 In this study we look to the expression of surface markers in CML patients that 
are doing different therapies. So we did this additional analysis for the expression of 
CD4, CD8, CD7, CD57, CD62L, CD69, CD27, CD11b, CD137 and CD137L in 
CD56
bright
 and CD56
dim
 NK cells.   
For CD4 positive NK cells we demonstrate that the percentage of CD4
+
 
CD56
bright
 NK cells decrease proportionally with the increase of Imatinib dose, NK cells 
from ponatinib patient don’t seem to express CD4+ NK cells but we just had one patient 
so this result is poor and in the CD56
dim
CD16
+
 population the percentage of CD4
+
 cells 
is decreased in Dasatinib and other groups (figure 42.A). The percentage of CD8 
positive NK cells is equal for all groups in CD56
bright
 NK cells, in CD56
dim
 NK cells the 
Imatinib 400 group is the one with highest percentage of CD8 positive cells and the 
others group had the lowest percentage, with statistical significance (figure 42.B). The 
CD7
+
 NK cells are highly expressed by the two subpopulations with no significant 
differences among patient groups (figure 42.C). CD57 positive NK cells don’t differ 
much between the groups in both CD56
bright
 and 
dim
 NK cells, with the exception for the 
others group that show a decrease in CD8
+
 CD56
dim
CD16
+
 NK cells (figure 42.D). The 
expression of CD62L is high in the CD56
bright
 population from all groups with no 
significant differences between them, unless for the Dasatinib group where the CD62L 
positive cells tend to be low (figure 42.E). In the CD56
dim
 population the percentage of 
CD62L positive cells increase a bit in the others and ponatinib groups (figure 42.E). 
CD56
bright
CD16
-
 NK cells from the Imatinib 400 and others group have the highest 
percentage of CD69
+
 cells in the CD56
dim
CD16
+
 NK cells the percentage of CD69
+
 
cells is low in all groups (figure 42.F). For the expression of CD27 only in the 
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CD56
bright
CD16
-
 NK cells a decrease is noticed, for the remaining groups no differences 
are shown, independent of the NK cell subpopulation (figure 42.G). The percentage of 
CD11b positive cells no differences were observed between the groups in study in both 
CD56
bright
 and CD56
dim
 NK cells (figure 42.H). Finally, we study the differences in the 
same groups for CD137 and CD137L positive cells. The percentage of CD137 positive 
NK cells is highest in the Dasatinib and ponatinib groups and the lowest percentages are 
related with the IFN-α and others groups  comparing with the individuals doing Imatinib 
400 (figure 42.I). The percentage of CD137L
+
 CD56
bright
CD16
-
 NK cells is highest for 
the Imatinib 400, decreasing with the dosage of Imatinib, as we can see in the Imatinib 
600 group. Further that a more accentuated decreased is noticed for the Dasatinib group 
and the lowest frequencies belong to the IFN
-α and others groups. In the CD56dimCD16+ 
subpopulation the percentage of CD137L
+
 cells don’t differ much, although in Imatinib 
600 and Dasatinib groups this percentage is relatively reduced comparing with others 
groups (figure 42.J). 
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Figure 42: The expression of cell surface markers in CD56brightCD16- and 
CD56dimCD16+ NK cells, according with the defined groups. Imatinib 400 (n=18); Imatinib 
600 (n=8); Imatinib 800 (n=8); Dasatinib (n=5); Ponatinib (n=1); IFN-α (n=3); Others (n=7). A 
– The expression of CD4 in CD56bright and CD56dim NK cells from the different groups of 
individuals. B – The expression of CD8 in CD56bright and CD56dim NK cells from the 
different groups of individuals. C – The expression of CD7 in CD56bright and CD56dim NK 
cells from the different groups of individuals. D – The expression of CD57 in CD56bright and 
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CD56dim NK cells from the different groups of individuals. E – The expression of CD62L in 
CD56bright and CD56dim NK cells from the different groups of individuals. F – The 
expression of CD69 in CD56bright and CD56dim NK cells from the different groups of 
individuals. G – The expression of CD27 in CD56bright and CD56dim NK cells from the 
different groups of individuals. H – The expression of CD11b in CD56bright and CD56dim NK 
cells from the different groups of individuals. I – The expression of CD137 in CD56bright and 
CD56dim NK cells from the different groups of individuals. J – The expression of CD137L in 
CD56bright and CD56dim NK cells from the different groups of individuals.   
   
NK cell receptors expression in CD56brightCD16- and CD56dimCD16+ 
populations varies with different therapies. 
  
 As we saw before NK cells have a vast repertoire of receptors. In order to 
understand how different therapies affect these cells in terms of receptors. All samples 
are performed with extracellular labelling and then acquired on cytometer as described 
in chapter II. For the receptor expression by NK cells we study five groups of 
individuals, Imatinib 400 (n=18), Imatinib 600 (n=8), Imatinib 800 (n=8), Dasatinib 
(n=5) and others (n=7). 
 For the KIRs we study KIR2DL1, KIR2DS1 and KIR2DL2.  The receptor 
KIR2DL1 is highly expressed by CD56
bright
CD16
-
 NK cells from Dasatinib group and 
those who are doing Imatinib 800 also express more KIR2DL1 comparing with Imatinib 
400 group, with statistical significance (figure 43.A). In the CD56
dim
CD16
+
 population 
the Imatinib 400 group is the one that express more KIR2DL1, whereas the other groups 
have reduced expression of this receptor (figure 43.A). KIR2DS1 expression is poor by 
CD56
bright
CD16
-
 NK cells independently of therapy. About the CD56
dim
CD16
+
 
population we observed a higher expression in the Dasatinib group comparing with the 
Imatinib 400 group (with statistical significance) and the other groups express less this 
receptor (figure 43.B). CD56brighCD16
-
 NK cells almost not express KIR2DL2 with no 
significant differences between the groups in study (figure 43.C). In the CD56
dim
CD16
-
 
population the expression of KIR2DL2 is higher for the Imatinib 600 group in 
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comparison with Imatinib 400 group and the Dasatinib group seems to express less this 
receptor (figure 43.C). The expression of these KIRs is independent of dosage. 
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Figure 43: The expression of KIRs in CD56brightCD16- and CD56dimCD16+ NK cells, 
according with the defined groups. Imatinib 400 (n=18); Imatinib 600 (n=8); Imatinib 800 
(n=8); Dasatinib (n=5); Others (n=7). A – The expression of KIR2DL1 in CD56bright and 
CD56dim NK cells from the different groups of individuals. B – The expression of KIR2DS1 in 
CD56bright and CD56dim NK cells from the different groups of individuals.   C – The 
expression of KIR2DL2 in CD56bright and CD56dim NK cells from the different groups of 
individuals.   
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Beyond KIRs we also analyzed the effect of therapy in the expression of NCRs 
by NK cells, namely NKp30, NKp44, NKp46 and C
-
type lectin
-
like receptor NKp80. 
Comparing the expression of NKp30, by CD56
bright
CD16
-
 NK cells, between the 
Imatinib 400 group and the other groups, we demonstrated that only the others group 
express less this NCR (figure 44.A). Doing the same comparison for the CD56
dim
CD16
+
 
cells we saw that the Imatinib 600 group express more and the Dasatinib group 
practically not express NKp30 (figure 44.A). The NKp44 expression is augmented in 
the Imatinib 600, 800 and Dasatinib groups for CD56
bright
 NK cells and for CD56
dim
 NK 
cells hardly noticed expression in all groups (figure 44.B). For NKp46 expression the 
CD56
bright
 cells have a higher rate than CD56
dim
 cells, but between groups no significant 
differences were found. Although in the CD56
dim
CD16
+
 NK cells apparently occurs an 
effect of Imatinib dosage, because the NKp46 expression increases with the higher dose 
of this drug (figure 44.C). NKp80 is greatly expressed by both subpopulations of NK 
cells, being independent of therapy or dosage, with exception for the CD56
bright
 NK 
cells in Dasatinib group, where NKp80 expression is reduced (figure 44.C). 
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Figure 44: The expression of NCRs in CD56brightCD16- and CD56dimCD16+ NK cells, 
according with the defined groups. Imatinib 400 (n=18); Imatinib 600 (n=8); Imatinib 800 
(n=8); Dasatinib (n=5); Others (n=7). A – The expression of NKp30 in CD56bright and 
CD56dim NK cells from the different groups of individuals. B – The expression of NKp44 in 
CD56bright and CD56dim NK cells from the different groups of individuals.  C – The 
expression of NKp46 in CD56bright and CD56dim NK cells from the different groups of 
individuals. D – The expression of NKp80 in CD56bright and CD56dim NK cells from the 
different groups of individuals.     
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Cytokine production by NK cells is affected by CML therapy.     
 
Finally, we made a research about the effect of CML in the cytokine production 
by NK cells. By intracellular labelling we study the NK cell production of IL-4, IL-10, 
TGF-β and IFN-γ in seven different groups of CML patients. However, for some groups 
not all cytokine information can be assessed. Looking to the CD56
dim
CD16
+
 NK 
population we saw that these cells are very deprived of cytokine production, at least for 
the cytokines studied (figure 45). So we concentrated our attention in the 
CD56
bright
CD16
-
 population. Comparing with the Imatinib 400 group, the CD56
bright
 NK 
cells from CML patients doing IFN-α produce more IL-4, whereas Imatinib 600 and 
Dasatinib patients produce less (figure 45.A). IL-10 production is augmented in the 
Dasatinib, ponatinib and others group, with statistical significance (figure 45.B). For 
TGF-β the ponatinib and others group shows a higher production in comparison with 
Imatinib 400 group and the Imatinib 600 group express less, with statistical difference 
(figure 45.C). About the IFN-γ production all groups express less than the Imatinib 400 
group, namely the Imatinib 600, 800 and ponatinib group (figure 45.D).  
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Figure 45: Cytokine production by CD56brightCD16- and CD56dimCD16+ NK cells from 
patients undergoing different therapies. Imatinib 400 (n=18); Imatinib 600 (n=8); Imatinib 
800 (n=8); Dasatinib (n=5); Ponatinib (n=1); IFN-α (n=3); Others (n=7). A – The percentage of 
IL-4+ CD56brightCD16- and IL-4+ CD56dimCD16+ NK cells. B – The percentage of IL-10+ 
CD56brightCD16- and IL-10+ CD56dimCD16+ NK cells. C – The percentage of TGF-β+ 
CD56brightCD16- and TGF-β+ CD56dimCD16+ NK cells. D – The percentage of IFN-γ+ 
CD56brightCD16- and IFN-γ+ CD56dimCD16+ NK cells. 
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Effect of BCR
-
ABL clones in NK cells from CML patients  
 
 Another objective of this study is tried to understand if the amount of BCR
-
ABL 
clones affect in some way NK cells. In our lab, the amount of BCR
-
ABL is quantified in 
order to monitorize the CML patients. With access to this information we divided CML 
patients in five groups, one negative for BCR
-
 ABL – until 0, 01% BCR/ABL (n=34) 
and four positives for BCR
-
 ABL – until 0, 1% (n=2), 1% (n=4), 10% (n=4) and 100% 
(n=5) of BCR/ABL. The negative group served as control.  
The percentage of total lymphocytes, NK cells and NK cells subpopulations don’t 
differ with the ratio BCR/ABL. 
 
The percentage of lymphocytes is higher for the negative group, in the other 
groups the percentage of lymphocytes varies but not much (figure 46.A). For the 
proportion and count of NK cells the 0, 1% BCR/ABL group of individuals has the 
upper percentage and in the other groups this percentage doesn’t differ significantly 
from the negative group (figure 46.B.C). Within the NK cell population no differences 
are reported in the groups of study (figure 46.D). 
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Figure 46: Percentage of total lymphocytes, NK cells and NK cells subpopulations from 
CML patients according to BCR/ABL ratio. A – Percentage of lymphocytes. B – Percentage 
of NK cells C – Count of NK cells. D – Percentage of CD56brightCD16- and CD56dimCD16+ 
NK cells. 0, 01% BCR/ABL (n=34) 0, 1% BCR/ABL (n=2), 1% BCR/ABL (n=4), 10% 
BCR/ABL (n=4) and 100% BCR/ABL (n=5). 
A B 
 
C 
 
D 
  
 
Chapter IV – Discussion and Conclusions 
 
  
   
Discussion 
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NK cells are potent and aggressive killers of tumor cells, so tumor cells need to 
change and modify their microenvironment to escape recognition and attack by NK 
cells (61).  CML is a myeloproliferative disease subdivided in three characteristic 
phases; chronic phase (CP) of CML is characterized by excess numbers of myeloid cells 
that proliferate extensively. Between 90% and 95% of patients will be diagnosed in this 
phase of the disease. If untreated, within an average of 4 to 6 years, the disease 
transforms through an accelerated phase (AP) to an invariably fatal acute leukemia, also 
known as blast crisis (BC). Disease progression is likely due to the accumulation of 
molecular abnormalities that lead to a progressive loss of the capacity for terminal 
differentiation of the leukemic clone. The current treatment tries to maintain remission 
and prevent progression of the disease to AP and BC while minimizing any therapy
-
related toxicity (40,41). Early studies were shown that NK cells selectively lyse CML 
progenitor cells in vitro. In accelerated CML and blast crisis, NK cell proliferation, lytic 
function and frequency seems to decline, but until now remains unclear whether this 
decline is a cause rather than an effect of disease progression. Additionally, donor vs 
recipient NK cell alloreactivity could eliminate leukemia in human transplants (62). As 
follows, understanding the mechanisms of the NK cell dysfunction in CML could be 
useful in elucidating how this disease develops and in identifying therapeutic strategies. 
In this study we analyzed the NK cell immunoprofile from CML patients and 
healthy donors, including surface molecules (e. g. CD57, CD7), receptors (KIRs, C
-
type 
Lectin
-
like receptors and NCRs), some adhesion molecules (e.g. DNAM-1) and some 
cytokines (e.g. IFN-γ, TGF-β). After characterization of CML NK cells we investigated 
whether therapy and drug dosage incomes or not effect on NK cells.  
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The percentage of total lymphocytes and their subpopulation is decreased in CML 
patients. 
  
Lymphocytes are immune cells originated from lymphoid hematopoietic stem cells, 
after differentiation in thymus they become T cells, B cells or NK cells. As potent tolls of the 
immune system is important to study how these immune cells are affected by malignant cells, 
many studies reported that tumor microenvironment could suppress the immune system but the 
mechanisms behind such evidences stands unclear (8). In leukemia patients the T cell 
dysfunction is associated with disease progression, which may be due to a disorder in the thymic 
output function, the abnormal expression of TCR and, possibly, abnormal TCR signal 
transduction through altered CD3 gene expression (54). The percentage of lymphocytes is 
reduced in CML patients as described for other diseases. The T cells and B cells are diminished 
in naïve patients however in CML patients these percentages return to normal levels, revealing a 
positive effect of therapy. About NK cells we will discuss later. Additionally, in de novo CML 
have been reported decreased levels of CD4
+
 and CD8
+
 T cells (63), what is coherent with our 
results where the absolute numbers of CD4
+
 and CD8
+
 cells are decreased compared with 
healthy controls, specially the CD8
+
 T subpopulation is drastically reduced. Other investigators 
reported a decrease in CD8
+
 T cells in other diseases and they hypothesized that such decrease  
may underlie the persistent immunodeficiency found in patients (64).  
The proportion of CD56
bright
 and CD56
dim
 NK cells in healthy donors and CML 
patients is comparable, but CML patients have higher percentage of total NK cells.  
 
 Preceding studies suggest that NK cells play an important role in controlling 
growth of CML cells and sustaining complete molecular response (CMR) and , recently, 
CML patients who sustained a CMR after Imatinib discontinuation were shown to 
exhibit higher levels of functional NK cells than either normal subjects (63). In 
scientific literature some studies evaluate the NK cells in patients with viral infections, 
but in peripheral blood no quantitative alterations were described. Except in three kids 
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with herpetic encephalitis, that present an important reduction in percentage and in 
absolute number of NK cells (65). Our results confirm that CML patients under 
treatment have an increase on NK percentage and cell count, and this increased wasn’t 
observed in naïve patients, what suggest that therapy potentiate the immune response by 
increasing the NK cells frequency, at least in peripheral blood. About the relative 
proportions of CD56
dim
 and CD56
bright
 NK cells in disease less has been known, and in 
our reports no differences between healthy donors and CML patients are conveyed.  
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Expression of cell surface markers by CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK 
cells from CML patients 
 
 The expression of cell surface markers displays some characteristics of NK cells, 
like activated NK cells (e.g. CD69, CD4), maturation stages (e.g. CD11b, CD27 and 
CD57), and structural properties involved in NK cell mechanisms (e.g. DNAM-1) 
(49,53). Analyzing some of these markers we conclude that NK cells from CML 
patients have different expression profiles which imply differences in NK cell 
recognition and effector functions. 
The percentage of CD4 positive CD56
bright
CD16
-
 NK cells is reduced in CML 
patients and the percentage of CD8 positive CD56
bright
CD16
-
 NK cells is higher in 
CML patients. 
 
CD4 is normally expressed on helper T cells, where it plays an important role in 
the recognition of MHC molecules on the surface of adjacent cells (66). Recently, 
studies demonstrated that activated NK cells express CD4 molecule on their surface 
(67).  Our data confirms that NK cells express CD4 on their surface and interestingly 
NK cells from CML patients express less this marker. But there is no clues so far that 
explain the role of CD4 on NK cells functions.  CD8 is another antigen usually 
expressed on CTLs, which interacts with HLA-I molecules. Previous studies 
demonstrated that CD8 engagement delivers an activating signal which increases the 
synthesis and secretion of Fas
-
L and ultimately it leads to NK cell apoptosis through the 
interaction of soluble Fas-L with Fas (68). The expression of CD8 by NK cells from CML 
patients is slightly increased compared with healthy donors, which in accordance with prior 
studies reflects an increase in NK cell apoptosis against tumor cells, in this case treatment seems 
to induce a higher expression of CD8. 
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CD56
bright
CD16
-
 NK cells from CML patients have a higher expression of CD7 per 
cell and CD56
dim
CD16
+
 NK cells from naïve patients have a higher expression of 
CD57 per cell, in comparison with healthy controls. 
 
The function of CD7 on NK cells is barely unstudied. CD7 is a member of the 
immunoglobulin superfamily(67). CD56
bright
 NK cells from CML patients have a higher 
expression of CD7 per cell, but further studies about the contribution of CD7 on NK 
cells are needed to understand what this CD7 increase actually means. The expression 
of CD57, a cell surface glycoprotein, on NK cells is well known, until now the 
expression of CD57 is associated with NK cell and T cells terminal maturation and 
differentiation. Thus CD57 allows the differentiation between CD56
bright
 and CD56
dim
, 
which express less and more CD57 respectively (49). Herein we demonstrate that 
CD56
dim
 NK cells are most of all CD57
+
, in naïve patients the expression of CD57 per 
cell is highly augmented compared with healthy controls but in CML patients this not 
occurs. Maybe NK cells from naïve patients are “so old”, elucidated by the increase in 
CD57 surface density, that loss their capacities.  
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CML patients NK cells have higher expression of CD27 in CD56
bright
CD16
-
 subset. 
The percentage of CD11b
+
 NK cells is augmented in CD56
bright
 subset of cml 
patients and the surface density of cd11b is higher in both CD56brigh and CD56
dim
 
NK cells.     
 
Recent studies have reported that CD27 belongs to TNF receptor family and allows the 
differentiation between NK
-
cell subsets in murine and human. The surface density of 
CD27 and CD11b in NK cells may reflect different stages of differentiation too (69). 
Our results confirm that CD56
bright
 cells has higher expression of CD27 and less 
expression of CD11b than CD56
dim
NK cells, in agreement with the definition of 
CD56
dim
 NK cells as the more mature NK cells. The CD27 expression by NK cells from 
healthy or CML patients is equivalent. However, the percentage of CD11b in CD56
bright
 
NK cells is increased in CML patients, which indicates a greater degree of maturation in 
CD56
bright
 population. Such premature development could affect the function of 
CD56
bright
 NK cells, by losing their immunomodulatory character. 
In CD56
bright
CD16
-
 NK cells, the percentage of CD62L
+
 and CD69
+
 cells and their 
surface density is augmented in CML patients. 
 
CD62L is an adhesion molecule that mediates the primary interaction of immune cells 
with the vascular endothelium and the homing of CD56
bright
 NK cell subset to secondary 
lymphoid tissues (29). The lack of CD62L expression has been linked to NK cell degree 
of cytotoxicity and the majority of CD62L
-
 NK cells were found to be CD56
dim
 NK 
cells (29), so higher expression of CD62L means a minor degree of cytotoxicity by NK 
cells. Our results show an increase in CD62L expression in CML patients in both NK 
cell subsets. Some studies in T lymphocytes reported that CD62L down
-
regulation 
accompanies T lymphocyte activation and is thought to redirect cells away from lymph 
nodes to sites of infection, parallel with NK cells maybe in CML patients the 
upregulation of CD62L prevents that NK cells turn activated (70). By contrast, CD69 
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molecule is rapidly upregulated on NK cells and other lymphocytes when they are 
activated (71). Human peripheral blood NK cells express CD69 after their stimulation 
by IL
-
2 or IFN
-α. This activation antigen represents a triggering surface molecule in NK 
cells as its stimulation triggers the cytolytic machinery of these cells. However, so far 
the, mechanisms regulating the expression of CD69 in are unknown (71,72). In our 
studies CML patients have a higher percentage of CD69
+
 CD56
bright
 NK cells whereas 
have a lower percentage of CD69
+
 CD56
dim
 NK cells. However, for both NK subsets the 
surface density of CD69 is bigger in CML patients. Thus we conclude that NK cells 
from CML patients express more CD69 in order to increase their activity. 
The surface density of CD137L and CD137 and the CD137
+
 cell percentage is 
augmented in both CD56
bright
 and CD56
dim
 NK cells from CML patients; the ratio 
CD137/CD137L in CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells is augmented in 
CML patients. 
 
There are numerous studies in mice supporting the notion that NK cells are 
involved in the elimination of tumor cells. CD137 belongs to the TNFRSF and has been 
reported to enhanced the proliferation and survival of activated CD4
+
 and CD8
+
 T cells 
in humans (73). Furthermore, its expression has been reported on NK cells (74). In 
AML it was demonstrated that CD137L was expressed on leukemic cells and interacts 
with CD137 on activated NK cells. The interaction CD137/CD137L induces cytokine 
release (IL-10 and TNF-α) by AML cells, which defect granule mobilization, 
cytotoxicity and IFN
-γ production. In our studies we detected a higher expression of 
CD137 by CD56
bright
 and CD16
dim
 NK cells from CML patients as demonstrated for 
AML. And the ratio CD137/CD137L is also augmented in NK cells from CML patients 
(73–75). Additionally, as we saw the expression of TNF-α is increased in CML patients 
evidencing the correlation between CD137/CD137L and the production of TNF
-α in NK 
cell, as demonstrated in AML patients. 
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The expression and surface density of CD96, DNAM-1, CD155 and TIGIT of CML 
patients don’t differ, significantly, from healthy donors. 
 
 DNAM-1, CD96 and TIGIT belong to an new family of receptors that interact 
with nectin and nectin
-
like proteins. DNAM-1 induces NK cell
-
mediated cytotoxicity, 
whereas TIGIT counterbalances the effect of DNAM-1.By contrast, despite CD96 
shares the ligand CD155 with DNAM
-
1 and TIGIT their role has remained unclear (76). 
Previous studies shown that DNAM-1 plays a crucial role in tumor immune surveillance 
mediated by NK cells and CTLs and, in human cancers, NK cells may express low 
levels of DNAM-1 as a result of tumor
-
mediated activity. For example blocking the 
interaction of DNAM-1 with its ligands results in inhibition of NK cell cytotoxicity 
against carcinomas and hematopoietic tumors (76,77). In our study the particular 
frequency of these four markers is equal for healthy donors and CML patients, but 
further studies are needed to deduce if expression of DNAM-1, TIGIT and CD96 on NK 
cells from CML patients could effectively be involved in the disease development.  
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The expression and surface density of PD-1, PD-L1 and PD-L2 of CML patients 
don’t differ, significantly, from healthy donors. 
 
 PD-1 is a programmed death receptor T cell expression of PD-1 downregulatas 
the immune response against malignancy by engagement of them cognate ligands (PD
-
1 
or PD
-
2) expressed on tumor cells (54,78). However, little is known concerning PD-1 
and NK cells. Recent studies in chronic HIV-1 infection described that raised levels of 
PD-1 were associated with limited NK cell proliferation, which may have consequences 
for their maintenance during disease (79). We just did a quick research about PD-1, PD-
L1 and PD-L2 in T cells, NKT cells and NK cells from CML patients, and comparing 
with healthy donors there is no evidence for PD-1 role in CML. 
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Receptor repertoire of CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells from healthy 
donors and CML patients 
 
NK cells are cells with the mission to defend the body immediately against 
pathogens or in the early stages of tumor development. As a consequence, the 
recognition receptors of NK cells are displayed on the cell surface without the need of 
assembly, i.e., rearrangements from multiple DNA segments after antigenic encounter. 
After recognition NK cells are regulated by a balance of signals delivered from 
activating and inhibitory receptors as we saw before.   
KIR2DL1, KIR2DL2 and KIR2DS1 expression is altered in CML patients. 
 
The highly polymorphic KIR receptor family encodes the main MHC
-
monitoring molecules on primate NK cells and includes both inhibitory and activating 
members. KIRs are transmembrane glycoproteins containing two (D1 and D2) or three 
(D0, D1 and D2) extracellular C2
-
type Ig
-
like domains. KIRs with two Ig
-
like domains 
are designated KIR2D; KIRs with three Ig
-
like domains are designated KIR3D. 
Whereas KIR2D receptors bind HLA
-
C alleles, KIR3D receptors bind HLA
-
A and 
HLA
-
B alleles, In addition, they have either short (S) or long (L) intracytoplasmatic tails 
which transduce activating or inhibitory signals, respectively(80). However our results 
shows that KIR2DL1 in heathy  donors is highly expressed in CD56
bright
 NK cells and 
poorly expressed by CD56
dim
 NK cells, in literature KIRs are expressed preferably on 
CD56
dim
 NK cells than in CD56
bright
NK cells (80). KIR2DL1 is an activating receptor of 
NK cells and its expression is drastically decreased on CD56
bright
 NK cells from CML 
patients, in healthy control almost CD56
bright
 NK cells express KIR2DL1 whereas in 
CML patients CD56
bright
 NK cells practically not express this receptor. So KIR2DL1 is 
downregulated by the disease or treatment condition leading to an impaired NK cell 
activity. In contrast, KIR2DL2, also an activating receptor, is relatively upregulated on 
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CD56
dim
 NK cells what it means that NK cells are expressing more activating KIR2DL2 
improving their cytotoxic activity. In the other hand, KIR2DS1 expression seems to be a 
little high in CD56brigh NK cells. Different KIR repertoires were identified in CML 
patients and healthy donors, but the mechanisms behind such modifications remain 
unclear.   
The NKG2A expression and surface density on CD56
bright
CD16
-
 NK cells and the 
surface density of NKG2C on CD56
dim
CD16
+
 NK cells is decreased in CML 
patients, and the ratio NKG2C/NKG2A are increased in both NK subsets. 
 
Human NKG2 molecules belong to the C
-
type lectin family (81). CD94 forms 
hetero
dim
ers with NKG2A or with NKG2C that bind with its ligand HLA
-
E. Binding 
HLA
-
E with CD94:NKG2A conveys an inhibitory signal, by contrast with 
CD94:NKG2C an activating signal is transduced to NK cells (82). The CD94/NKG2A 
complex is expressed on most normal NK cells, namely on CD56
bright
 NK cells, whereas 
CD94/NKG2C complex is poorly express on resting blood NK cells although the 
expression can be regulated by the cytokine environment and might be affected by 
ongoing infections (83).  Our studies confirm that NKG2A is expressed essentially on 
CD56
bright
 NK cells, further that in CML patients the NKG2A expression is drastically 
reduced which could represent a positive effect of CML treatment on NK activity, once 
NK cell inhibiting control is less effective. In the other hand, NKG2C expression is 
augmented in CD56
dim
 NK cells, cytotoxic NK cells. This receptor is an activating 
counterpart for the inhibitory CD94/NKG2A hetero
dim
er (83) and the ratio between 
NKG2C/NKG2A is increased on CML patients. Furthermore the expression of CD94 is 
unimpaired in CML patients (data not shown). We hypothesized that NKG2A and 
NKG2C expression on NK cells is inversely correlated, and in CML patients something 
is upregulating NKG2C expression inhibiting the expression of NKG2A, consequently 
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the NK cells overcomes the rest state and be active against leukemic cells. However, 
further studies are needed to understand if these facts are consequence of disease rather 
than cure. 
NKp30, NKp44, NKp46 and NKp80 expression by NK cells between CML patients 
and healthy controls is different. 
 
Another NK cell receptor family consists exclusively of activating receptors 
known as NCRs, including NKp30, NKp44, and NKp46. The expression of such 
markers is restricted to NK cells as well as NKp80. NKp80 is a C
-
type lectin
-
like 
receptor that function as a co
-
receptor with NCRs to induce activation of NK cell
-
mediated cytolysis (41,84) and in our results there is no difference for NKp80 
expression in NK cells from CML patients . NCRs trigger lysis of tumors and virus 
infected cells (85). Earlier studies shows that NKp30 and NKp46 are constitutively and 
selectively expressed on all peripheral NK cells whereas NKp44 is expressed only on 
activated NK cells (84,85). NKp46, NKp30 and NKp44 bind molecules expressed by 
tumor cells(86), and in some diseases as acute myeloid leukemia (AML) the down
-
regulation of activating receptors NKp30 and NKp46 correlates with defective NK cell 
cytotoxicity and poor leukemia prognosis(87). In our studies the expression of NKp30 is 
downregulated mainly on CD56
dim
 NK cells, what suggests a weaker NK cell cytotoxic 
activity, since activating receptor its less expressed NK cell recognition of tumor cells 
through NKp30 is deficient.  NKp46 expression is increased in NK cells from CML 
patients, such increased should be correlated with the recognition of molecules 
expressed by leukemic cells, increasing NKp46 upregulation on NK cells and activating 
them. NKp44 is a characteristic receptor of activated NK cells, and in our studies we 
identify a decrease in NKp44 expression on NK cells from CML patients, possibly 
tumor microenvironment upregulate the expression of ligands recognized by inhibitory 
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receptors on NK cells inhibiting their activation, these could explain the low frequency 
of NKp44
+
 NK cells in CML patients.   
Cytokine production by CD56
bright
CD16
-
 and CD56
dim
CD16
+
 NK cells from healthy 
donors, naïve and CML patients 
 
With a multiplicity of receptors evolved to sense cellular homeostasis and 
distress, NK cells are well equipped to act as primary initiators of immune responses 
upon recognition of infected or neoplastic cells. Such responses are not confined to 
cytotoxic effector mechanisms, but also involve the secretion of cytokines and 
chemokines. In this line we observed the frequency of some cytokines like interleukins 
(IL-4 and IL-10), TNF-α, TGF-β and IFN-α in NK cells from CML patients. 
The cytokine production by NK cells is impaired in naïve and CML patients, 
comparing with healthy donors. 
 
Our results shows that NK cells from naïve patients produced more interleukins 
(IL-4 and IL-10) than healthy controls, although NK cells from treated CML have a 
reduced production of ILs, less than controls. Interleukins are proteins that mediate 
cellular communication. The biological effect of IL-10 is anti
-
inflammatory and 
immune suppressive(88). So an elevated production of IL-10 by NK cells could 
suppress immune response against leukemic cells in untreated CML patients, in order to 
escape to NK cell activity. The normal levels are restored after treatment, since NK cells 
from CML patients have lower production of IL-10. Other studies confirm that NK cell 
expression of IL-10 downregulate the immune response (29). About IL
-
4 production by 
NK cells not much is known but in our report IL-4 expression is similar to IL-10 
expression by NK cells in healthy donors, naïve and CML patients.  Like IL-10, TGF-β 
is also a cytokine with immune suppressive effects. TGF-β antagonizes IL-15, a 
cytokine that induces NK cell proliferation and activation (87). Our results show that the 
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percentage of TGF-β+ NK cells from CML patients is reduced; however the expression 
of TGF-β per cell is augmented in both NK subsets from CML patients. Previous 
studies shown that TGF-β mediates inhibition of surface expression of NKp30 (89) and 
in our study low expression of NKp30 in CD56
dim
 NK cells is confirmed.  Suggesting 
that TGF-β suppresses NKp30 expression, thus inhibiting NK cells cytotoxicity. 
Besides that some reports defend that release of TGF-β upregulate MHC-I expression on 
tumor cells and downregulate expression of NK cell activating receptors such as NKG2D 
and their ligands (89). Among all NK cells produced cytokines, TNF-α and IFN-γ are 
critical in early host defense pathways, to help to control the spread of intracellular 
pathogens (29). Following activation, NK cells are well known to produce and express 
several types of cytokines, for instance IFN-γ that influence other types of immune cells 
such as T cells and DCs. IFN-γ, as our results confirmed, is predominantly produced by 
CD56
bright
 NK cells (90). In CML patients rate of IFN-γ produced by NK cells its 
greatly increased, which means that the production of IFN-γ is positively affected in NK 
cells from CML patients, signifying higher NK cell cytotoxicity. TNF-α, another 
proinflammatory cytokine produced by NK cells, member of the tumor necrosis factor 
receptor super family (TNFRST)  and their ligands in the tumor necrosis factor 
superfamily members (TNFSF)  have been suggested to be involved in the activation 
and maturation of  NK cells (91). In patients with CML the NK cells CD56brigh and 
CD56
dim
 express TNF
-α in higher amounts then NK cells from healthy donors, so NK 
cells from CML patients are more cytotoxic than those from healthy donors. 
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Effect of CML therapies, biologic or TKI therapy, and dosage in NK cells 
 
 As we saw before, TKI therapy revolutionized the CML treatment. Imatinib was 
the first drug used in CML treatment and stands as standard drug for CML patients. 
Despite the success of Imatinib, some patients do not respond or develop resistance 
against Imatinib. Concerning these patients novel TKIs are introduced in market, second 
and third generation TKIs that overcomes some limitations of Imatinib (1,49,52). 
Recent observations indicated that TKIs have inhibitory and/or stimulatory effects on 
immune cells, via modification of markers in surface of tumor cells. Some reports 
focused on NK Cells show that Imatinib have no impact on NK cytotoxicity or cytokine 
production, whereas nilotinib negatively influenced cytokine production (1). Several 
studies try to report the effect of Dasatinib on NK cells and although 
immunosuppressive effects were initially observed in preclinical studies, recent 
evidence suggests Dasatinib may activate and mobilize anti
-
leukemic immune 
responses, improving efficacy (92). About ponatinib effect on NK cells little information 
is available until now. Herein, we report the latter results but dividing CML patients 
according to therapy as described is results. 
The percentage of lymphocytes is independent of therapy and dosage, but the 
percentage of NK cells differs, evidenced on CD56
bright
 NK cells percentage.  
 
 Although total lymphocytes are reduced in CML patients, no differences exist 
between the therapy groups which means that the current treatment for CML don’t 
affect the total lymphocyte frequency in peripheral blood cells (49). NK cells are 
decreased in number in CML patients; however the Dasatinib group has increased NK 
cell number, which indicates that Dasatinib induce NK cell restore by the immune 
system (92). Another interesting finding is that those patients who are doing IFN
-α have 
a higher percentage of CD56
bright
 NK cells compared with other therapies, in accordance 
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with this report, increased counts of NK cells have also been reported for IFNα-treated 
CML patients who were able to discontinue treatment without relapse (63). Recent 
studies shows that IFN
-α combined with TKIs is more effective than TKI by himself 
(93), and the increase in NK cell frequencies could be another positive insight for IFN
-α 
in current treatment of CML. Plus, CD56
bright
 NK cells seems be lower in patients with 
higher doses of Imatinib (42,53) but in our studies this difference is minimal.  
NK cells from patients undergoing different therapies have different expression of 
surface markers and receptors as well as different cytokine production. 
 
 Bringing together our results in order to compare the different kinds of therapy 
that the patients in study are doing we conclude that different therapy, biologic or TKI, 
different TKI drug and its dosage are crucial factors in disease development. As we can 
see in table 1 many direct or indirect effects have been reports about TKIs on NK cells 
(1,42). In this specific study we demonstrate that Imatinib 600 and Imatinib 800 patients 
have less production of IFN-γ and TNF-α and less expression of NKG2C. Furthermore 
KIR2DL1 and KIR2DL2 expression is augmented in Imatinib 800 and Imatinib 600 
patients, respectively. Both cytokines and NKG2C are players in active immune 
response. Thus, weak expression by NK cells from Imatinib 600 and 800 patients in 
addition with the high expression of inhibitory KIRs results in a defective NK cell 
function, confirming the critical role of Imatinib dose on NK cells. Other researchers 
reported that Dasatinib induce alterations on NK cells, but the critical effects in this 
cellular population remain undiscovered  (92).  NK cells from Dasatinib patients have 
reduced expression of CD69 and higher production of IL-10, CD69 data indicates that 
NK cells are less activated and the production of IL-10 seems to suppress NK cell 
activity, both occurrences point to NK cell dysfunctional activity probably caused by 
Dasatinib drug. Plus, KIR2DL1 expression is augmented in NK cells such as the 
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expression of NKp80 and NKp30 is decreased, one more time the inhibitor receptors are 
overexpressed whereas activating receptors are under expressed. The decrease in 
NKp30 expression was before related with other leukemias like AML (87). Ponatinib is 
the newest TKI used in CML treatment, so few studies exist about this drug until now. 
In our research we analyzed one ponatinib patient so the results for Ponatinib group are 
poorly founded. However an increased in TGF-β production is reported. For IFN-α and 
others subject was evidenced that the expression of CD27 is decreased in CD56
bright
 NK 
cells, showing that IFN-α didn’t affect so strongly NK cells like TKIs. At present, IFN-
α has been combined with Imatinib for CML treatment and investigators have reported a 
higher effectiveness and less parallel effects on immune cells from those patients (54).   
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Effect of BCR-ABL clones in NK cells from CML patients 
 
Several studies reported that NK cells from blood of CML patients are 
progressively decreased in number as the disease progresses from chronic phase to blast 
crisis (94). So is hypothesized that BCR
-
ABL
+ 
clones per patient may be directly 
responsible by interfering with NK cell differentiation and function(93,94). As we saw 
in the introduction the BCR
-
ABL oncogene encodes a constitutively activated tyrosine 
kinase that affects proliferation, mobilization and differentiation of BCR
-
ABL
+
 cells 
(41). 
The percentage of total lymphocytes, NK cells and NK cells subpopulations don’t 
differ with the ratio BCR/ABL. 
 
 The percentage of BCR-ABL clones is directly correlated with disease severity. 
Disease remission is achieved when the ration BCR/ABL is below than 0.01%, when 
the BCR-ABL ratio exceeds this value means that therapy is not being effective. Thus 
the BCR-ABL ratio allows monitorize the treated CML patients (95). In our study we 
conclude that the higher ratio of BCR-ABL clones in blood samples from CML patients 
not significantly affect neither the percentage of lymphocytes or percentage and NK 
cells count. 
 
 
 
 
 
  
 
  
Conclusions and Future Perspectives 
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The concluding remarks of the present research are that the frequency of total 
lymphocytes and NK cells is decreased at diagnosis and in treated CML patients. The 
expression of surface markers such as CD7, CD57, CD27, CD11b, CD62L, CD69, 
CD137 and CD137L are altered in CML patients. The receptor NK cell repertoire from 
CML patients is different from healthy donors, namely KIR2DL1, NKG2A, NKG2C, 
NKp30, NKp44 and NKp46. NK cells from CML patients produce more IFN
-γ and less 
IL-4, IL-10 and TGF-β. Besides that the current therapies used in CML treatment have 
different effects on NK cells subpopulations, specially the patients undergoing 
Dasatinib or IFN-α, the effects of dosage is not so evident. A briefly research was made 
for patients with low to high percentage of BCR/ABL and no significant differences are 
found but further studies are needed in this field. NK cells as we demonstrate in this 
study are altered in CML patients and these alterations disturb the NK cell homeostasis 
preventing NK cell effector mechanisms against leukemic cells. In literature have been 
reported NK cell changes in other diseases, viral infections and cancer, and in the last 
decade many researches focus their attention into understand NK cell biology and 
mechanisms in order to potentiate cytokine production and cytotoxicity against tumor 
cells.  Therefore NK cells are emerging as a powerful tool in immunotherapy. 
Next, we hope to be able to analyze others interesting markers that could be key 
points of the disease and preform genetic studies of NK cells from CML patients to 
confirm the present results and bring new discoveries. Concluding, I think that NK cells 
may be the future of immunotherapy not only in CML as well as other diseases. 
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Table 2: Antibodies used in present research. 
 
1F12 Monoclonal antibody  
8C11 Monoclonal antibody 
CD11b (ITGAM) Cluster of Differentiation 11b 
CD137 (4-1BB) Cluster of Differentiation 137 
CD137L Cluster of Differentiation 137 Ligand 
CD14 Cluster of Differentiation 14 
CD155 (PVR) Cluster of Differentiation 155 
CD158a Cluster of Differentiation 158a 
CD158b Cluster of Differentiation 158b 
CD16 Cluster of Differentiation 16 
CD19 Cluster of Differentiation 19 
CD27 Cluster of Differentiation 27 
CD3 Cluster of Differentiation 3 
CD4 Cluster of Differentiation 4 
CD56 (NCAM1) Cluster of Differentiation 56 
CD57 Cluster of Differentiation 57 
CD62L (L-selectin, LAM-1) Cluster of Differentiation 62L 
CD69 Cluster of Differentiation 69 
CD7 Cluster of Differentiation 7 
CD8 Cluster of Differentiation 8 
CD96 Cluster of Differentiation 96 
DNAM-1 (CD226) DNAX Accessory Molecule
-
1 
NKG2A  Natural killer group 2A 
NKG2C Natural killer group 2C 
NKp30 (NCR3) Natural Killer protein 30 
NKp44 (NCR2) Natural Killer protein 44 
NKp46 (NCR1) Natural Killer protein 46 
NKp80 (KLRF1) Natural Killer protein 80 
PD-1 Programmed death receptor
 
1 
PD-L1 Programmed death receptor ligand 2 
PD-L2 Programmed death receptor ligand 1 
TIGIT T cell immunoreceptor with Ig and ITIM domains 
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Figure 47: Analysis of the distribution of KIR2DL1, KIR2DL2 and KIR2DS1 on natural 
killer (NK) cells by combining the antibodies 1F12, 8C11, CD158a and CD158b. A/B – 
8C11 and CC158b combined to KIR2DL1 measurement; C/D – 8C11 and CD158a combined to 
KIR2DS1 measurement; E/F – 1F12 and CD158b combined to KIR2DL2 measurement. The 
graphs on the left are related to CML patients (n=10) and the graphs on the right are related to 
healthy controls (n=4). 
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Figure 48: Mean of fluorescence intensity of 1F12, 8C11, CD158a and CD158b in 
CD56bright and CD56dim populations. A – Mean of fluorescence intensity of 1F12 in 
CD56
bright
 and CD56
dim
 NK cells. B – Mean of fluorescence intensity of 8C11 in CD56bright and 
CD56
dim
 NK cells. C – Mean of fluorescence intensity of CD158a in CD56bright and CD56dim NK 
cells. D – Mean of fluorescence intensity of CD158b in CD56bright and CD56dim NK cells. The 
blood samples are collected from CML patients (n=10) and healthy donors (n=4). 
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